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It is estimated that over 500,000 million people worldwide suffer from disease 
associated with intestinal inflammation, including gastric cancer, inflammatory bowel 
disease, h. pylori infections, and numerous vial and bacterial infections.  Although 
potentially effective therapeutics exist for many of these pathologies, delivery challenges 
thwart their clinical viability.  For example, due to their specificity and efficacy, RNA 
interference (RNAi)-based therapeutics have been heralded as next generation 
therapeutics that are anticipated to revolutionize the treatment of inflammatory and 
infectious diseases.  However, their rapid systemic clearance of RNAs and their potential 
off target toxicities have kept these therapies from transitioning from the laboratory to the 
bathroom shelf.  In addition to potentiating new therapies for diseases associated with 
intestinal inflammation, novel delivery strategies could also improve the efficacy, while 
reducing the toxicity, of drugs currently in use.  Chemotherapeutics currently used to 
treat colitis-associated cancer are extremely toxic and actually induce drug resistance by 
activating prosurvival pathways in tumors.  For this reason, delivery strategies that 
localize chemotherapeutics to CAC tumors and block drug resistance would dramatically 
enhance the treatment of CAC. 
The objective of this work was to develop drug delivery platforms that could 
target immunomodulator therapeutics to diseased intestinal tissues and thus improve the 
treatment of diseases associated with intestinal inflammation.  To meet this objective we 
developed an oral delivery vehicle for siRNA and an NF-κB inhibiting nanoparticle that 
reduces drug-resistance.  A summary of the development of these two delivery platforms 
is presented below.   
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Small interfering RNA (siRNA) represents a promising treatment strategy for 
numerous gastrointestinal (GI) diseases associated with chronic intestinal inflammation; 
however, the oral delivery of siRNA to inflamed intestinal tissues remains a major 
challenge.  In this chapter, we present a delivery vehicle for siRNA, termed thioketal 
nanoparticles (TKNs), that can orally deliver siRNA to sites of intestinal inflammation, 
and thus inhibit gene expression in diseased intestinal tissue.  TKNs are formulated from 
a new polymer, poly-(1,4-phenyleneacetone dimethylene thioketal) (PPADT), that 
degrades selectively in response to reactive oxygen species (ROS).  Therefore, when 
delivered orally, TKNs target the release of encapsulated agents to the elevated levels of 
ROS specific to sites of intestinal inflammation1-3. Using a murine model of ulcerative 
colitis (UC), we demonstrate that orally administered TKNs loaded with TNFα-siRNA 
(TNFα-TKNs) diminish TNFα messenger RNA (mRNA) levels in the colon and protect 
mice from intestinal inflammation.  Given the prevalence of intestinal inflammation in GI 
diseases2, and the therapeutic potential of siRNA4, we anticipate numerous applications 
of the TKNs for treating GI diseases.    
Activation of nuclear factor-κB (NF-κB) results in the expression of numerous 
prosurvival genes that block apoptosis, thus mitigating the efficacy of 
chemotherapeutics.  Paradoxically, all conventional therapeutics for cancer activate NF-
κB, and in doing so initiate drug resistance.  Although adjuvant strategies that block NF-
κB activation could potentiate the activity of chemotherapeutics in drug resistant tumors, 
clinical evidence suggests that current adjuvant strategies also increase apoptosis in 
non-malignant cells.  In this chapter, we present a nanoparticle, formulated from a 
polymeric NF-κB-inhibiting prodrug, that can target the chemotherapeutic irinotecan 
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(CPT-11) to solid tumors, and thus abrogate CPT-11-mediated drug resistance and 
inhibit tumor growth.  In order to maximize the amount of NF-κB inhibitor delivered to 
tumors, we synthesized a novel polymeric prodrug, termed PCAPE, that releases the 
NF-κB inhibitor caffeic acid phenethyl ester (CAPE) as its major degradation product.  
Using a murine model of colitis-associated cancer, we demonstrated that when 
administered systemically, CPT-11-loaded PCAPE-nanoparticles (CCNPs) are three 
time more effective than a cocktail of the free drugs at reducing both tumor multiplicity 
and tumor size.  Given the central role played by NF-κB activation in drug resistance and 












Chapter 1:  Introduction 
Controlled inflammation is an essential part of numerous salubrious physiological 
processes such as wound healing5, cancer surveillance6, and defense from invading 
pathogens.  However, aberrant inflammation, caused by the deregulated expression and 
activation of proinflammatory mediators, is a central factor in the onset and persistence 
of numerous gastrointestinal (GI) diseases, including inflammatory bowel disease7,8 
(IBD), gastric cancers6,9, h. pylori infection10, and viral infections11.  Thus, delivery 
platforms that could target immune suppressive agents to diseased intestinal tissues 
would improve the treatment of numerous diseases associated with intestinal 
inflammation.  For example, unabated expression of the proinflammatory cytokine tumor 
necroses factor-α (TNFα) is an initiating and exacerbating phenomenon in the 
pathophysiology of IBD5.  In this clinical setting, nanoparticles formulated from a 
biomaterial that degrades selectively in the presence of reactive oxygen species (ROS), 
which are produced excessively in inflamed intestinal tissues, could ferry anti-TNFα 
small interfering-RNAs through the GI tract then release them in response to the 
elevated ROS levels specific to inflamed intestinal tissues12-15.   
Localized delivery of immunosuppressive agents could also improve the 
treatment of colitis associated cancer (CAC)16-18.  Despite the initial response to 
treatment, most CAC tumors treated with chemotherapeutics develop drug resistance 
and experience tumor regrowth and metastasis19-21.  Recent studies indicate that 
chemotherapeutics activate the proinflammatory transcription factor-κB (NF-κB), which 
up regulates the expression of numerous prosurvival genes, thereby mitigating their 
efficacy22-26.  For this reason, a delivery vehicle that could target both an NF-κB inhibitor 
and chemotherapeutic to tumors could abrogate drug resistance, thus potentiating the 
tumor to chemotherapy induced apoptosis.    
2 
 
Our long-term goal is to develop drug delivery platforms that target therapeutics 
to diseased intestinal tissues.  The objective of this proposal was to develop biomaterials 
that have the chemical and physical properties needed to either target orally delivered 
siRNA to inflamed intestinal tissues or inhibit chemotherapy-induced drug resistance in 
CAC tumors.  The central hypotheses of this proposal were that:  1. Nanoparticles 
formulated from a thioketal-containing polymer that degrades selectively in the presence 
of ROS would have the stability to protect siRNA from the harsh environment of the GI 
system, but the sensitivity needed to target siRNA to inflamed intestinal tissues; and 2. 
Nanoparticles formulated from a polymeric NF-κB inhibitor can co-localize the delivery of 
an NF-κB inhibitor and chemotherapeutic to CAC tumors, and thus improve the therapy 
of CAC by blocking NF-κB-mediated drug resistance.   
The overall objective was accomplished by testing our central hypothesis in the 
following specific aims: 
 
Specific Aim I:  Design and synthesis of ROS-sensitive polymers for the oral 
delivery of siRNA to treat intestinal inflammation.  We hypothesized that polymers 
formulated from ROS-sensitive thioketal linkages would resist hydrolysis and enzymatic 
cleavage, but degrade selectively in the presence of the elevated ROS levels specific to 
inflamed tissues.  In this study, siRNA against TNFα, a known protagonist of IBD, was 
encapsulated in nanoparticles formulated from polythioketals (TKNs) and delivered orally 
via daily gavage to mice with an experimental form of IBD.  After 7 days, mice were 
sacrificed and colon samples analyzed for mucosal TNF-α mRNA, extracellular TNF-α 
levels, and disease progression.  A head-to-head comparison with relevant controls and 
siRNA-loaded PLGA nanoparticles was performed to assess the unique ability of TKNs 




Specific Aim II:  Treating CAC via NF-κB inhibiting nanoparticles that co-loclize 
the delivery of a chemotherapeutic and NF-KB inhibitor to tumors, and thereby 
prevent chemotherapy-induced drug resistance. 
We hypothesize that the NF-κB inhibitor caffeic acid phenethyl ester (CAPE) can 
potentiate the anti-tumor effect of the chemotherapeutic Irinotecan (CPT-11) by inhibiting 
the activation of NF-κB.  The ability of the NF-κB inhibitor CAPE to improve the efficacy 
of CPT-11 on HT-29 cancer cells was investigated and a mechanism for improved 
efficacy suggested.  Polymers that incorporate the NF-κB inhibitor CAPE into their 
backbone were synthesized and characterized.  CPT-11-loaded nanoparticles 
formulated from CAPE containing polymers were generated and characterized.  The 
efficacy of the CPT-11-loaded CAPE nanoparticles versus appropriate controls was 
























Chapter 2:  Project Significance 
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s 
Disease, is an idiopathic autoimmune disorder that affects millions of people worldwide 
and is characterized by chronic uncontrolled inflammation of the intestinal mucosa27,28.  
Although IBD causes less than 1000 mortalities per year in the United States (US), it is a 
tremendous burden on the medical infrastructure and the economy.  In the US alone, 
IBD accounts for nearly 1.1 million ambulatory care visits per year and costs 1.6 billion 
dollars a year to treat29.  Furthermore, since IBD affects people in the prime of their life, 
IBD results in 3.6 billion dollars of lost productivity per year30.  For this reason, strategies 
to treat IBD would decrease health care expenditures and increase medical access for 
patients suffering from more critical diseases.  
Currently, IBD is an incurable condition, for which treatment options are limited30.  
First-round therapeutics include corticosteroids, however, approximately 30% of IBD 
cases are steroid resistant31.  Additionally, corticosteroids have many potentially life 
threatening side effects, including obesity, psychosis, and heart failure32,33.  In the last 
decade, biological therapeutics, such as monoclonal antibodies for the proinflammatory 
cytokine TNFα and TNFα receptor antagonists, have significantly improved the 
treatment of IBD34. While these biologics are more effective than corticosteroids, they 
too have potentially deadly side effects35.  The use of TNFα targeting therapies has been 
associated with an increased risk of cancer, tuberculosis, and heart failure36.  
Furthermore, these therapeutics must be delivered via injection.          
Here, we describe a new class of ROS-sensitive biomaterials, termed 
polythioketals, that have the properties needed to orally deliver siRNA and target 
inflamed mucosal tissue.  Polythioketals have the stability needed to survive the extreme 
pHs of the gastrointestinal (GI) tract and resist cellular proteolysis, but degrade in the 
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presence of ROS37.  These unique properties endow orally delivered siRNA-loaded 
polythioketal nanoparticles (TKNs) with the ability to transport anti-TNFα siRNA (TNFα-
siRNA) through the acidic environment of the stomach, release it in inflamed mucosal 
tissues, and inhibit TNF-α gene expression in the GI tract.  Due to their stability, oral 
availability, and ability to target inflammation, TKNs have several advantages over 
existing delivery vehicles for siRNA38.  TKNs loaded with TNF-siRNA can be formulated 
via a single emulsion solvent evaporation procedure that produces particles that can be 
lyophilized and stored as a dry powder, unlike liposomal delivery vehicles.  Furthermore, 
since polythioketals are delivered orally, we expect improved patient compliance over 
injectable and suppository based siRNA delivery vehicles39.  Finally, by localizing TNFα-
siRNA to sites of intestinal inflammation, TKNs reduce the potential toxicity caused by 
the system suppression of TNFα40.  
Although the total number of cancer related mortalities has declined over the past 
ten years, the worldwide mortality rate of colorectal cancer has increased steadily over 
that same period of time41,42.  Today, more than 1 million new cases of colorectal cancer 
(CRC) are diagnosed each year worldwide 41.  CRC is the third most common cancer 
and the fourth most common cause of cancer related mortality in the world43.  Although 
advances in early detection and chemotherapy have decreased the number of CRC 
mortalities in the United States (US), CRC remains the third  most common cause of 
cancer related death in the US 43.  Current first-round therapies for CRC include surgery 
and radiotherapy; however, 32% of patients receiving these interventions experience a 
relapse within 12 months42.  These resurrected tumors are usually addressed with toxic 
chemotherapeutics that can have devastating side effects, and paradoxically activate the 
critical factors within the tumor that are responsible for drug resistance44.  The rising rate 
of CRC mortalities, the toxicity of current second-round therapeutics, and the prevalence 
of reoccurrence, underscore the need for new therapeutic strategies to treat CRC.   
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Accumulating clinical and genetic evidence indicates that CRC’s proclivity for 
avoiding the effects of chemotherapeutics is a result of NF-κB activation 45.  NF-κB is a 
transcriptional activator that has been extensively studied for its role as a central 
regulator of the inflammatory response46. Recently, it has become clear that NF-κB plays 
a pivotal role in drug resistance by elevating the expression of numerous genes that 
promote survival, proliferation, and metastasis 47.  Consequently, NF-κB activation is an 
excellent predictor of tumor prognosis as well as resistance to chemotherapy and 
radiotherapy 25.   
Despite the overwhelming evidence indicating that blocking NF-κB inhibits drug 
resistance and thus improves the efficacy of chemotherapeutics, there has yet to be a 
successful clinical trial on this approach23,48.  A major obstacle block the development of 
such therapeutic strategies is the increased toxicity of NF-κB inhibition in non-malignant 
cells that are normally targeted by chemotherapeutics49.   Here, we present the 
development of a novel drug delivery platform that can target CAC tumors, inhibit drug-
resistance by blocking NF-κB activation, while simultaneously delivering a 
chemotherapeutic.  The ability of this technology to target an NF-κB inhibitor and 
chemotherapeutic to solid tumors should decrease the toxicity of the combined 










Chapter 3:  Review of relevant literature 
3.1.   Specific Aim I 
3.1.1.  Oxidative Stress is central to inflammatory bowel disease 
The central focus of Specific Aim I is on the targeting of siRNA to inflamed 
mucosal tissue under oxidative stress via an ROS-sensitive delivery vehicle.  Although 
the exact role of ROS in the etiology of UC remains uncertain, abnormally high levels of 
ROS are produced in the colons of patients with UC50.  This abnormally high level of 
ROS is produced from activated neutrophils that congregate in inflamed mucosal 
tissues51.  The overproduction of ROS by these activated neutrophils is so severe that it 
damages gap junctions between mucosal epithelial cells leading to bacterial infiltration 
and infection, which ultimately results in leukocyte infiltration and increased oxidative 
stress 52.  These high levels of oxidative stress in patients with UC provide a molecular 
signature for inflammation and can be targeted with ROS-sensitive biomaterials.        
          
3.1.2. ROS-cleavable polymers  
Materials that can target siRNA to mucosal tissues under oxidative stress by oral 
delivery must be composed of ROS-sensitive linkages that are stable to both acidic and 
photolytic cleavage.  A linkage that meets these criteria is the thioketal.  Thioketals have 
been used extensively in organic synthesis as oxidation sensitive protecting groups for 
carbonyl compounds53.    
As protecting groups, thioketals are particularly useful because they are stable to 
acid and base catalyzed hydrolysis.  Thioketal protecting groups are formed by 
performing a Lewis Acid-catalyzed condensation reaction between a carbonyl compound 
and ethane-1,2-diol.  Thioketals can also be found in the structure of some 
pharmaceutical compounds and are known to cleave under biologically relevant levels of 
ROS54.  In the past 8 years, traditional acetals, or ketals, have been incorporated into the 
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backbones of biodegradable polymers using the acetyl exchange reaction between 
various diols and 2,2-dimethoxypropane 55-57.  This synthetic strategy produces 
traditional polyketal polymers with molecular weights ranging from 4000–6000 Da.  
Polythioketal polymers have been used to formulate microparticles that encapsulate both 
hydrophobic small molecules and proteins58,59.  We anticipated that the flexibility of the 
acetal exchange reaction can be used to synthesize homo- and copolymers that contain 
the ROS-sensitive thioketal linkage in their backbones.   
 
3.1.3. TNF-α is a protagonist in the development and persistence of UC 
The experiments in this proposal will develop an oral siRNA delivery vehicle 
based upon an ROS-sensitive biomaterial.  In the experiments proposed below, anti-
TNF-α siRNA will be delivered to inflamed mucosal tissue as a treatment for ulcerative 
colitis (UC).  Although the exact pathogenesis of UC is not well understood, TNF-α has 
been shown to play an integral role in the development of the disease 60,61.  Several 
studies have demonstrated that fresh colonic mucosal biopsies of UC patients show 
increased levels of TNF-α expression62,63.  Pharmacologic studies have also 
demonstrated the importance of TNF-α in the pathophysiology of UC.  Small molecule 
inhibitors of TNF-α are efficacious in mouse models of UC64.    Multiple clinical trials 
have demonstrated the efficacy of monoclonal antibodies against TNF-α in the treatment 
of UC65,66.    Although these antibodies are highly effective, nearly 25% of patients taking 
the monoclonal antibody Infliximab® experienced at least one serious adverse event, 







3.2.  Specific Aim II 
3.2.1.  Intestinal inflammation, NF-κB, and CRC 
Rudolf Virchow made the first observation of the symbiotic relationship between 
inflammation and cancer in 1863 when he observed that human tumors are often 
festooned with leukocytes6.  In the last decade, the ying-yang relationship between 
inflammation and cancer has been well established by genetic, pharmacological, and 
epidemiological data67-71.  Nearly 20% of all cancers arise in association with infection or 
chronic inflammation, and nearly all of those that are not, contain elevated levels of 
inflammatory mediators38.  Colitis-associated cancer (CAC) represents the archetype for 
the link between inflammation and cancer, given its high frequency in patients with IBD, 
the protective role of nonsteroidal anti-inflammatory drugs67, and CAC’s association with 
inflammatory gene expression72.  Recently, scientists have begun to elucidate the 
mechanisms by which immune cells, cytokines, ROS, and reactive nitrogen species 
contribute to the three phases of tumor development, namely initiation, promotion, and 
progression73.   
 The transcription factor NF-κB is well established as a central regulator of 
numerous proinflammatory genes such as cytokines, cytokine receptors, and cell 
adhesion molecules69.  More recently, NF-κB activation has been implicated as being 
involved with multiple aspects of tumorigenesis, including the control of genes that 
control survival, angiogenesis, proliferation, adhesion, and metastasis41,74-76 (Figure 3.1).  
Studies performed on mice suffering from experimental CAC, demonstrated that NF-κB 
activation was necessary for both tumorigenesis as well as tumor growth74.  Clinical 
studies performed on patients suffering from ulcerative colitis have demonstrated that 
NF-κB activation in the colon is an excellent predictor of the probability of CAC 




Figure 3.1.  Ilistration of NF-κB activation pathway and the protumorigenic and prosurvival 
genes initiated by its activation. Upon phosphorylation by the IKK complex IκB is degraded, 
liberating NF-κB and allowing it to translocate to the nucleus.   
 
In addition to cancer development, NF-κB activation is the primary mechanism by 
which cells avoid treatment by chemotherapeutics77-79.  In its inactive form, NF-κB is 
sequestered in the cytoplasm by a family of NF-κB binding proteins called IκB (Figure 
3.1).  In response to activating stimuli, including cytokines and DNA-damaging agents, 
IκB is phosphorylated by the IκB kinase complex (IKK), which leads to IκB ubiquitination 
and subsequent degradation by the proteosome80.  The degradation of IκB liberates NF-
κB allowing it to translocate to the nucleus, where it increases the expression of a variety 
of prosurvival genes, including Bcl-xL, IAP, FLIP and survivin81-84.  These genes block 
the effects of chemotherapeutics and generate a drug resistant state in the cell26.  
3.2.2. Irinotecan:  Mechanism of action, NF-κB activation 
Since its introduction in 1996 Irinotecan (CPT-11) has improved the prognosis of 
patients suffering from CAC and metastatic CRC85,86.  CPT-11 is an analog of 








































cleaved by host enzymes to give 7-ethyl-10-hydroxy-camptothecin (SN-38), which is 
100-fold more potent than CPT-1187.  Irinotecan has been used clinically to treat CRC, 
esophageal cancer, gastric cancers, lung cancer, leukemia, and various gliomas88.  
Irinotecan causes S-phase specific cell death by targeting cellular topoisomerase I (Topo 
I)-DNA complexes.  Topoisomerase I binds to double-stranded DNA and cleaves the 
phosphate backbone of one of the DNA strands to reduce the twisting and supercoiling 
that occur in selected regions of DNA during DNA transcription, replication, and repair89.  
Irinotecan interacts with the Topo I-DNA complex after DNA-strand cleavage to form a 
covalent Topo I-DNA reaction intermediate90.  Although nonlethal by itself, the enzyme-
DNA complex generated by Irinotecan halts the advancement of the replication fork, and 
in doing so generates a double-stranded DNA-break on the leading strand of the newly 
synthesized DNA.  This double-stranded break terminates DNA replication and causes 
the death of the dividing cell.   
Although double-stranded DNA damage is lethal and causes cell-cycle arrest, the 
DNA damage caused by CPT-11 activates cytoplasmic signaling cascades that liberate 
active NF-κB from its inhibitor protein, IκBα, through an IKK-dependent pathway that 
does not require extracellular signaling via the classical or alternative pathways21.  In this 
way, CPT-11 initiates the tumor cells’ central defense mechanism against 
chemotherapy, inducing drug resistance.   Numerous clinical and experimental studies 
have verified the link between CPT-11 and induced drug resistance in CRC91,92.  CRC 
tumor biopsies taken from patients before and after first-round treatment with CPT-11 
showed elevated levels of NF-κB activation after CPT-11 treatment48.  CPT-11 has also 
been shown to increases NF-κB activation in a dose and time dependent manner in 
numerous colon cancer cell lines including LoVo93, HCT-1523, HCT 11684, Caco-223, 
colon2624, and the CPT-11 resistant cell line HT-2926.  Additionally, tumor xenografts 
formed from HT-29, HCT-116, or colon26 cells showed elevated levels of NF-κB 
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activation post treatment with CPT-1123,24,26.  In order to demonstrate the drug resistance 
inducing power CPT-11, Lagadec et al. showed that at a dose of 30 mg kg-1, CPT-11 
increases the activation of NF-κB and the expression of the down-stream anti-apoptotic 
genes Bcl-xl, c-IAP1, and Survivin in HT-29 xenografts tumors in mice26.  These clinical 
and experimental results suggest that reducing NF-κB activation in concert with CPT-11 
treatment may help prevent CPT-11-mediated drug resistance, and in doing so increase 
CPT-11 efficacy.   
The first preclinical experiments demonstrating the synergy between NF-κB 
inhibition and CPT-11 in a colon cancer xenograft were performed  with an adenoviral 
delivery vector94.  In this work, mice bearing LoVo xenografts were treated once a week 
for three weeks with both CPT-11(33 mg kg-1 week-1, 21 days) and an adenovirus 
expressing a super-repressor IκBα that cannot be phosphorylated by IKK and thus 
inhibits NF-κB activation.  Mice treated with both CPT-11 and the adenovirus 
experienced no increase in tumor size over the 21 days of treatment, whereas mice 
treated with only CPT-11 or the adenovirus experienced tumor growth equivalent to the 
untreated animals. Given the clinical issues with adenovirus delivery of genes, Kokura et 
al. demonstrated a significant decrease in tumor size as well as lung metastasis when 
mice bearing colon26 tumors were treated with the radical scavenger edaravone and 
CPT-11 (30 mg kg-1 day-1, 18 days) compared to mice receiving only edaravone or CPT-
1124.  This decrease in tumor size with the combination therapy was attributed to 
edaravone’s ability to inhibit NF-κB in colon26 cells via the scavenging of ROS.  
Although edaravone is only approved for use in Japan, these results verified the 
adjuvant effect of inhibiting NF-κB via a pharmacological agent in the treatment of colon 
cancer tumors with CPT-11 and the ability to inhibit NF-κB activation in tumors with a 
radical scavenger.  Recently, studies that used the IKK inhibitor AS602868 (25 or 100 
mg kg-1 week-1, 10 weeks)  in combination with CPT-11 in the treatment of HT29 
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xenograft tumors in mice demonstrated improved efficacy of the combined therapy 
versus the individual drugs85.    
Despite convincing preclinical and in vitro results that demonstrate the synergy of 
NF-κB inhibition and CPT-11 in the treatment of colon cancer, there has yet to be a 
successful clinical trial on the combination of an NF-κB inhibitor with CPT-11.  NF-κB 
inhibitors must be non-toxic to normal cells, minimally immunosuppressive, and have 
few side effects.  Given that NF-κB activation serves as the central anti-apoptotic 
mechanism for all cells, and not just cancer cells, NF-κB inhibitors could increase the 
toxicity of CPT-11 to the liver, immune system, and heart95-101.     
 
3.2.3. Caffeic Acid Phenethyl Ester (CAPE):  NF-κB inhibitor           
Despite the convincing preclinical and in vitro results that demonstrate the 
synergy of NF-κB inhibition and CPT-11 in the treatment of colon cancer, there has yet 
to be a successful clinical trial using the combination of an NF-κB inhibitor with CPT-11.  
Clinically viable NF-κB inhibitors must be non-toxic to normal cells, minimally 
immunosuppressive, and have few side effects102.  Given their low levels of toxicity and 
minimal side effects, food derived flavonoids that inhibit NF-κB are promising adjuvants 
for the treatment of colon cancer.  Among the natural flavonoids that inhibit NF-κB, the 
most hopeful candidate for treating cancer is caffeic acid phenethyl ester (CAPE).  
CAPE, which is an active component of propolis from honeybee hives, is a well-
documented inhibitor of NFκB103 that has anti-inflammatory and anti-carcinogenic 
properties, and has been used to treat animal models of ulcerative colitis104-107, ischemic 
injury108-135, pulmonary fibrosis136, myocardial infarct, and numerous cancer tumors137-154.   
Although the exact molecular mechanisms have yet to be fully elucidated, 
CAPE’s inhibition of NF-κB stems from its ability to reduce IKK activity and thereby 
inhibit IκBα’s phosphorylation, subsequent degradation, and release of NF-κB.  Given 
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that, CAPE’s polyphenolic catechol group is a powerful ROS scavenger and the ability of 
radical scavengers to inhibit IKK activation, the NF-kB inhibition induce by CAPE had 
been attributed to its prowess as an antioxidant.  A recent structure-activity study with 
non-ROS scavenging and ROS-scavenging CAPE analogues indicates that CAPE’s 
Michael reaction acceptor (MRA) and ethyl-aromatic ring play a role in its ability to inhibit 
NF-κB155.  In this study, both catechol and cinnaminic acid phenethyl ester, which has an 
MRA but no catechol group, were able to inhibit TNFα-induced NF-κB activation in HT-
116 cells, whereas phenpropionic acid phenethyl ester, which has neither a catechol nor 
a MRA, did not.     
Various studies have demonstrated the NF-κB inhibiting potential of CAPE in 
numerous cancer cell lines including prostate cancer PC-3156, breast cancer MCF-7138, 
malignant peripheral nerve sheath tumors, astrocytoma GRT-MG157, myeloid leukemia 
U-937158, human B-lymphoma159, and colon cancer HT-29, 26-L5160,161, CT-26 and HT-
116 cells.  McEleny et al investigated the effect of CAPE on reducing NF-κB activation 
by paclitaxel in PC-3 cells.  Their work concluded that at 25 µg/ml CAPE reduced 
paclitaxel NF-κB activation by 50% and that this reduction was sufficient to reduce the 
downstream activation of prosurvival genes including cIAP-1, cIAP-2, and XIAP.  
Although CAPE has yet to be used as an adjuvant in treating tumors,  CAPE has been 
effectively used as a standalone therapeutic and inhibits the growth of 6 glioma162 (1.0 
mg kg-1 day-1)  , cholangiocarcinoma MZ-CH1-1163(10 mg kg-1 day-1), and colon cancer 
CT-26 (10 mg kg-1 day-1)  xenograft tumors grown in mice.  In studies performed on MZ-
CH1-1 xenografts149, the level of NF-κB inhibition induced by CAPE was sufficient to 
reduce the expression of anti-apoptotic genes Bax, Bcl-2 in the tumor and thus increase 




Chapter 4:  Thioketal Nanoparticles Orally Delivery siRNA, 
Target Intestinal Inflammation and Suppress 
Proinflammatory Gene Expression* 
 
4.1.   Abstract 
Gene silencing via orally delivered small interfering RNA (siRNA) represents a 
promising treatment strategy for numerous gastrointestinal (GI) diseases associated with 
chronic intestinal inflammation; however, the oral delivery of siRNA to inflamed intestinal 
tissues remains a major challenge.  In this chapter, we present a delivery vehicle for 
siRNA, termed thioketal nanoparticles (TKNs), that can orally deliver siRNA to sites of 
intestinal inflammation, and thus inhibit gene expression in diseased intestinal tissue.  
TKNs are formulated from a new polymer, poly-(1,4-phenyleneacetone dimethylene 
thioketal) (PPADT), that degrades selectively in response to reactive oxygen species 
(ROS).  Therefore, when delivered orally, TKNs target the release of encapsulated 
agents to the elevated levels of ROS specific to sites of intestinal inflammation1-3. Using 
a murine model of ulcerative colitis (UC), we demonstrate that orally administered TKNs 
loaded with TNFα-siRNA (TNFα-TKNs) diminish TNFα messenger RNA (mRNA) levels 
in the colon and protect mice from intestinal inflammation.  Given the prevalence of 
intestinal inflammation in GI diseases2, and the therapeutic potential of siRNA4, we 






*  Adapted and Modified from “Orally delivered thioketal nanoparticles loaded with TNF-α-
siRNA target inflammation and inhibit gene expression in the intestines.” Wilson DS, 




Due to constant insult from luminal bacterial and food antigens, the intestinal 
mucosa is in a state of orchestrated inflammation, characterized by an intricate balance 
of proinflammatory and toleragenic mediators76.  Numerous pathologies including 
infections164, neoplastic transition165, and autoimmune disorders166 can disrupt the 
intestinal immune system’s regulatory process, resulting in a pathogenic inflammatory 
event.   Although, the exact etiology of each of these diseases is unique, the resulting 
intestinal inflammatory response is driven primarily by the aberrant production of the 
proinflammatory cytokine tumor necrosis factor-α (TNFα)76.  Given the central role of 
TNFα in orchestrating the intestinal inflammatory response, therapeutic strategies that 
target TNFα production in the intestines could improve the treatment of virtually every 
disease associated with intestinal inflammation.   
RNA interference (RNAi) strategies directed against TNFα, have a tremendous 
potential to treat disease associated with intestinal inflammation167.  Nevertheless, the 
systemic depletion of TNFα has been shown to compromises the immune system, thus 
resulting in an elevated risk of infection168, lymphoma169, and cardiac dysfunction170.  
Therefore, the immune suppressive power of anti-TNFα RNAi-based therapeutics, such 
as siRNAs, must be localized to sites of intestinal inflammation.  Oral delivery vehicles 
have direct access to the intestinal mucosa, and thus represent an ideal platform for 
localizing siRNA to diseased intestinal tissue.  Furthermore, by eliminating needles, oral 
delivery eases administration and eliminates the risk of disease transmission by 
contaminated needles.  Various delivery vehicles have been developed to orally deliver 
therapeutics to intestinal tissue171-173, yet none of these strategies have demonstrated 
the ability to protect siRNA from the harsh environment of the GI tract and silence gene 
expression in intestinal tissues.  
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To localize the delivery of siRNA to diseased intestinal tissue, we identified the 
abnormally high levels of ROS produced at sites of intestinal inflammation as a disease 
specific triggering mechanism for siRNA release2.  For example, biopsies taken from 
patients suffering from UC1,3,174, colon cancer175, and h. pylori infections2 have a ten- to 
hundred-fold increase in mucosal ROS concentrations that are confined to sites of 
disease development and correlate with disease progression.  To target intestinal 
inflammation we developed TKNs, which release encapsulated agents in response to 
ROS.  TKNs are formulated from PPADT, a new polymer composed of ROS-sensitive 
thioketal linkages176 that are stable to acid-, base-, and protease-catalyzed 
degradation176,177 (Figure 4.1.a).  Therefore, orally delivered TNFα-TKNs remain stable 
in the GI-tract, thereby protecting siRNA and preventing its release to non-inflamed 
tissues (Figure 4.1.b, upper panel).  In contrast, at sites of intestinal inflammation the 
elevated ROS levels trigger the degradation of the TNFα-TKNs, thus localizing the 








Figure 4.1.  Thioketal nanoparticles are formulated from a new ROS-sensitive polymer and 
release orally delivered siRNA at sites of intestinal inflammation.  (a)  PPADT is a new 
polymer composed of ROS-sensitive thioketal linkages (circled in red).  TNFα-TKNs were 
prepared by first precomplexing TNFα-siRNA with the cationic lipid 1,2-dioleoyl-3-
trimethylammonium-propane.  Next, these siRNA-DOTAP complexes were added to an organic 
solution containing PPADT.  A single-emulsion procedure was then used to produce particles with 
mean diameters of ~600 nm that contain 4.7 μg TNFα siRNA/mg particles.  SEM image shows 
TNFα-TKNs (scale bar represents 1.5 μm).  (b) When delivered orally, TNFα-TKNs remain stable 
in the harsh environment of the GI tract, protecting TNFα-siRNA and preventing its release to 
non-inflamed mucosal tissues.  However, at sights of intestinal inflammation, where infiltrating 
phagocytes produce unusually high levels of ROS, the TKNs degrade, thus releasing TNFα-
siRNA to the site of inflammation. (c)   PPADT 3 was synthesized using the acetal exchange 
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Unless otherwise noted, all reagents were used as received from Sigma. 
4.3.1. PPADT Synthesis and ROS sensitivity assay 
Briefly, a two-necked flask was charged with distilled benzene, 1,4-
benzenedimethanethiol 1 (1.0 eq) and  2,2-dimethoxypropane 2 (1.0 eq.), then equipped 
with a metering funnel and distillation head for removal of the methanol by-product.  The 
mixture was then stirred continuously and heated to 95 °C before a catalytic amount of 
re-crystallized p-toluenesulfonic acid (0.003 eq.) in distilled ethyl acetate was added to 
start the reaction.  After 1 h, a solution of 2,2-dimethoxypropane and distilled benzene 
was added to the metering funnel and the funnel stopcock was set so that a small 
amount of 2,2-dimethoxypropane (0.08 eq per h) was add drop-wise over a period of 12 
h.   The reaction was allowed to stir overnight before the resulting polymer was isolated 
by precipitation in cold hexanes.  The polymer was vacuum-dried and analyzed by 1H-
NMR (Burker DMX 400, 400MHz), 13C NMR, and gel permeation chromatography 
(Shimadzu).  1H-NMR:  Per repeating unit, (400MHz, CDCl3,) δ ppm 7.28 (4H), 3.85 
(4H), 1.60 (9H).  13C- NMR: (400 MHz, CDCl3
 
) δ ppm 129.54, 77.56, 77.25, 76.93, 35.03, 
and 31.01.   The molecular weight of the resulting polymer was approximately 9 kDa with 
a polydispersity of 1.8.  In order to assess the ROS-sensitivity of PPADT, PPADT was 
exposed to superoxide according to the procedure described in Reference 173.  
4.3.2. Preparation of CMFDA- and rhodamine B-loaded TKNs 
CMFDA (Invitrogen) and rhodamine B were encapsulated in TKNs via an oil-in-
water single-emulsion procedure.  Either CMFDA (1.0 mg) or rhodamine B (1.0 mg) 
were solubilized in dimethyl sulfoxide (DMSO) and added to a solution of PPADT (100 
mg) in dichloromethane (DCM) (500 μl).  This organic phase was then added to 10 mL of 
a 5% solution of polyvinyl alcohol (PVA) in pH 7.4 phosphate buffer saline (PBS) and the 
20 
 
biphasic mixture was homogenized (17,500 rpm) for 60 sec.   The resulting oil-in-water 
emulsion was then added to 60 mL of a 1% solution of PVA in PBS and stirred in an 
open container for 4 h to evaporate the DCM.  The resulting particles were isolated by 
centrifugation and washed three times with PBS to remove any residual PVA.  Finally, 
the particles were frozen at -75°C and lyophilized to obtain a fine powder.  Empty TKNs 
were formulated as described above without any dye.  Particles contained either 8.3 μg 
of CMFDA per mg of particles or 6.9 μg of rhodamine B per mg of particles.  For all 
particle formulations, particle size was determined by dynamic light scattering [DLS 
(Brookhaven Instruments Corporation)], and visual evidence of particle formation was 
obtained via a scanning electron microscope [SEM (Hitachi S-800)]   
 
4.3.3. Preparation of siRNA-loaded TKNs and PLGA nanoparticles 
Nanoparticles loaded with siRNA were generated by first preparing complexes 
between the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) then 
using the above single-emulsion protocol to encapsulate these complexes into 
nanoparticles.  The TNFα-siRNA sequence 5’- CAC AAC CAA CUA GUG GUG CUU-3’ 
(Dharmacon) or a scrambled non-specific siRNA sequence or Cy3-tagged scrambled 
siRNA sequence were complexed with DOTAP (Avanti Polar Lipids Inc.) by adding 400 
μl of a 187.5 μM solution of siRNA in nuclease free water to 400 μl of a 9.45 mM 
DCM/DOTAP solution.  To this two-phase solution was added 880 μl of MeOH and the 
resulting single-phase solution was vortexed for 60 sec.  Next, DCM (400 μl) and 
nuclease free water (400 μl) were added to the siRNA-DOTAP solution, and the solution 
was centrifuged (1000 g for 10 min) to separate the two phases.  Next, the organic 
phase (aprox. 800 μl) containing the DOTAP-siRNA complexes was collected and added 
to 50 mg of PPADT or PLGA.  This organic siRNA-DOTAP/PPADT mixture was then 
used to formulate oil-in-water single-emulsion particles as described above.  This 
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protocol produced TNFα-TKNs, Sc-TKNs, Cy3siRNA-TKNs, and TNFα-PLGA that 
contained 4.7, 4.1, 5.7 and 6.1 μg of siRNA per mg of particles, respectively. 
 
4.3.4. Preparation of TNFα siRNA loaded βGPs 
βGPs containing TNFα-siRNA were prepared exactly as described in Reference 
12. 
 
4.3.5. ROS-responsive release from TKNs in vitro 
RAW 264.7 macrophages (ATCC) were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and maintained at 
37°C in a humidified 5% CO2
 
 atmosphere.  Cells were seeded in 12 well culture plates 
(107 cells/well) and incubated with 0.2 mg/ml CMFDA-TKNs.  After 3 h, the cells were 
washed with PBS three times, and then treated with either DMEM/FBS, DMEM/FBS 
spiked with LPS or DMEM/FBS spiked with LPS and TEMPOL (2.5 mM & 5.0 mM).  
After 20 h, the media was removed and the cells were washed with PBS and suspended 
in 1.5 ml of PBS containing 1% FBS and 5 mM EDTA.  The cells were then passed 
through a 45 μm nylon mesh before being analyzed via fluorescence-activated cell 
sorting (FACS) to assess intracellular dye release.  FACS analysis was carried out on 
DB®  FACSVantageSE/DiVa® instrumentation, and the results were analyzed with 
FlowJow® software.    
4.3.6. in vitro silencing of TNFα expression via TNFα-TKNs 
RAW 264.7 macrophages were cultured as described above, and seeded in 12 
well culture plates (107 cells/well).  After 12 h, the cell media was replaced with a 
solution of DMEM/FBS containing one of the following treatments:  TNFα-TKNs, Sc-
TKNs, TNFα-TKNs, TNFα-βGPs, or siRNA-DOTAP complexes.  For treatments 
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containing siRNA cells received 23.0 μg siRNA/ml.  After 4 h of treatment, the media 
was removed, the cells were washed with PBS, and then treated with either normal 
DMEM/FBS or DMEM/FBS spiked with LPS (5 μg/ml).  After 24 h, 100 μl of media was 
collected from each sample and analyzed for TNFα via ELISA according to the 
manufactures protocol (eBioscience). 
 
4.3.7. Induction of colitis and oral TNFα-siRNA delivery 
Animal experiments were performed in female C57BL/6 mice (8wk, 17 – 20 g, 
Jackson Laboratories).  Mice were group housed under a controlled temperature (25 
°C), photoperiod (12:12-h light-dark cycle), and allowed unrestricted access to potables 
and standard mouse chow.  They were allowed to acclimate to these conditions for at 
least seven days before being included in experiments.  Colitis was induced by adding 
3% (wt./vol) DSS [35,000 Da, (ICN Biochemicals)] to their drinking water.  For each of 
the animal experiments, groups of mice were treated with DSS or regular water for 
seven days.  Mice were observed daily and evaluated for changes in body weight and 
development of the clinical symptoms of colitis.   Starting on day zero, mice receiving 
DSS were given a daily gavage of PBS (200μl) or a PBS solution (200μl) containing one 
of the following:  TNFα-TKNs, TNFα-PLGA, Sc-TKNs, TNFα-βGPs, or TNFα-DOTAP.  
Mice receiving siRNA-loaded particles or TNFα-DOTAP were treated with either 2.3 
mg/kg or 0.23 mg/kg of TNFα-siRNA or scrambled siRNA per day for five days.  Mice 
were sacrificed after seven days, and histological assessment of colonic inflammation 
was performed by hematoxylin and eosin (H&E) staining of 5 μm-colonic tissue sections 
and analyzed by microscopy (20X & 10X).  All animal experiments were approved by 
The Animal Care Committee of Emory University, Atlanta (IACUC ID:  156-2008) and 
were performed in accordance with the guide for the Care and Use of Laboratory 




4.2.8. Real time RT-PCR 
Total RNA was extracted from mouse colons using TRIzol (Invitrogen).  A 
reverse transcription (RT) reaction was performed on 2 µg of each sample and an oligo-
dT primer, using a RETROscript® System (Ambion Inc.).  Next, 10 ng of reverse-
transcribed cDNA, 400 nM of gene-specific primers, and the iQ SYBR Green Suppermix 
(Biorad) was amplified at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s and 60°C for 1 min.  The 36B4 expression levels were used as reference, 
and fold-induction was calculated by the Ct method as follows: ∆∆CT=(Ct Target – Ct 
36B4)DSS+Treatment - (Ct Target – Ct 36B4)DSS+ PBS
 
.  Thus producing results normalized against 
mice receiving DSS and treated with PBS.  The final data were then derived from 2-∆∆CT.  
The primers used were designed using the Primer Express Program (Applied 
Biosystems) and were as follows: TNFα sense 5’-AGG CTG CCC CGA CTA CGT-3’ 
antisense 5’-GAC TTT CTC CTG GTA TGA GAT AGC AAA-3’; IL-1β sense 5’-TCG CTC 
AGG GTC ACA AGA AA-3’ antisense 5’-CAT CAG AGG CAA GGA GGA AAA C-3’; IL-6 
sense 5’-ACA AGT CGG AGG CTT AAT TAC ACA T-3’ antisense 5’-TTG CCA TTG 
CAC AAC TCT TTT C-3’; IFN-γ sense 5’-CAG CAA CAG CAA GGC GAA A -3’ 
antisense 5’-CTG GAC CTG TGG GTT GTT GAC -3’. 
4.3.9. Myeloperoxidase (MPO) Activity 
Neutrophil infiltration into the colon was quantified by measuring MPO activity.  
Briefly, a portion of the colon was homogenized in 1:20 (w/v) of 50 mM phosphate buffer 
(pH 6.0) containing 0.5% hexadecyltrimethyl ammonium bromide on ice using a 
homogenizer (Polytron).  The homogenate was then sonicated for 10 s, freeze-thawed 
three times, and centrifuged at 14,000 rpm for 15 min.  The supernatant (14 µl) was then 
added to 1 mg/ml o-dianisidine hydrochloride and 0.0005% hydrogen peroxide, and the 
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change in absorbance at 460 nm was measured.  MPO activity was expressed as units 
per mg of protein, where one unit was defined as the amount that degrades 1 µmol of 
hydrogen peroxide per minute at 25°C. 
 
4.3.10. Targeting of Cy3-labed siRNA to inflamed tissues using TKNs 
Mice receiving DSS or normal water were given a daily gavage of a PBS solution 
(200μl) containing empty TKNs or Cy3siRNA-TKNs (50 mg/ ml) (total of four groups with 
n =3 per group).  After seven days, each mouse receiving DSS had lost at least 10% of 
their body weight and had elevated fecal blood levels consistent with disease 
development.  Organ samples (0.5 g - 0.9 g) were removed, washed with cold PBS, 
patted dry with a paper towel, and then homogenized in 1 ml of  PBS (Polytron).  
Samples were then centrifuged at 14,000 rpm for 30 min, and Cy3 was quantified in 100 
μl of the supernatant using a fluorometer (λex/λem
 
 = 550/570; Shimadzu).  To correct for 
the background fluorescence resulting from the tissue and residual PPADT, the 
fluorescence measured from organ samples taken from mice receiving empty TKNs was 
subtracted from the fluorescence measured in samples taken from animals treated with 
Cy3siRNA-TKNs.  Results are expressed as fluorescent units per gram of tissue. 
4.3.11. Release of Cy3-tagged siRNA in response to ROS in vitro 
A 0.4 mg/ml solution of Cy3siRNA-TKNs in PBS was prepared and added to an 
equal volume of PBS containing either:  2 mM hydroxide radical, 0.2 mM hydroxide 
radical, 2 mM KO2, or 0.2mM KO2.  Hydroxide radical is formed by mixing Fenton’s 
Reagent with H2O2.  Each sample was prepared in triplicate.  The samples were then 
agitated on a rotary shaker at room temperature for either 4 or 12 hours.  After 4 or 12 
hours, the particles were isolated from the solution via centrifugation.  Finally, the 
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amount of Cy3-siRNA released from particles was measured by analyzing the 
fluorescence of the supernatant (λex/λem
 
 = 535/590; Tecan). 
4.3.12. Measuring CMFDA and rhodamine B loading in TKNs 
CMFDA encapsulation was verified by dissolving CMFDA-loaded TKNs in 
dichloromethane (DCM) and extracting the dye from the organic phase into a 1N NaOH 
solution.  The aqueous phase was then neutralized with 1N HCl and analyzed for 
fluorescence (λex/λem = 490/525; Shimadzu).  rhodamine B-loading was quantified by 
dissolving Rho-TKNs particles in DCM then assaying the DCM solutions for fluorescence 
(λex/λem
 
 = 540/625).  To account for the auto-fluorescence of PPADT, empty TKNs 
solution were prepared as described above and the fluorescence of these solutions was 
subtracted from the fluorescence measured from the dye-loaded particles.   
4.3.13. Measuring siRNA loading in TKNs and PLGA nanoparticles 
The amount of siRNA encapsulated in siRNA containing particles was quantified 
by isolating the encapsulated siRNA and measuring the amount of siRNA retrieved from 
the particles with the double-stranded RNA binding dye SYBR Green (Invitrogen).  
Particles containing siRNA were solubilized in DCM and then washed with a 20mM 
solution of NaCl in nuclease free water to disrupt the siRNA-DOTAP complexes and 
isolate the encapsulated siRNA.  Empty TKNs were also solubilized and washed with a 
salt solution to determine the background.  The aqueous phases were then isolated and 
analyzed for siRNA concentration using SYBR Green according to the manufacture’s 
protocol.   
 
4.3.14. Measuring rhodamine release rate in intestinal fluids 
Rhodamine-loaded PLGA nanoparticles and rhodamine-loaded TKNs were 
incubated in simulated gastric fluid (pH 1.2, pepsin 0.32% w/v) and simulated intestinal 
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fluid (pH 7.5, pancreatin 1% w/v)  at 37°C on a rotary shaker.  On an hourly basis, 
particles were separated from the supernatant by centrifugation and the concentration of 
rhodamine released from the particles was determined by fluorescent spectroscopy.    
 
4.3.15. Cytotoxicity of TKNs and PLGA nanoparticles 
An MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] reduction 
assay was used to measure the cytotoxicity of TNFα-TKNs and TNFα-PLGA 
nanoparticles.  Macrophages (1X105 cells/well, 96-well plate) were incubated with either 
TNFα-TKNs or TNFα-PLGA at various concentrations (1.0 – 5.0 mg/ml).  After 28 hours, 
20 μl of MTT solution (5 mg/ml in PBS) was added to each well, and the cells were 
incubated for 2 h.  Next, the MTT solution was removed and the cells washed 2 X before 
adding 200 μl of dimethyl sulfoxide to each well to dissolve the resulting formazan 
crystals.  After 10 min of incubation, the absorbance at 585nm was measured using an 
Emax Microplate reader (Molecular Devices, Sunnyvale, CA,USA).  Normalized cell 





4.4.1. PPADT synthesis and ROS sensitivity 
PPADT was synthesized from 1,4-benzenedimethanethiol 1 and 2,2-
dimethoxypropane 2 via a step-growth polymerization that produces polymers with 
molecular weights (MN) of approximately 9,000 Da (Figure 4.1.c).  To investigate the 
specificity of PPADT for ROS, we incubated PPADT with either a superoxide solution, 
0.5 N HCl solution, or a 0.5 N NaOH solution and then analyzed the resulting product’s 
molecular weight via gel permeation chromatography (GPC).  The GPC traces shown in 
Figure 2a demonstrate that exposing PPADT to superoxide decreases its molecular 
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weight from almost 9,000 Da to approximately 810 Da in 8 h, whereas incubating 
PPADT in either an acidic or basic environment had no effect on its molecular weight.   
 
4.4.2. TKNs release encapsulated agents in response to cellular ROS 
The unusually high concentrations of ROS localized to sites of intestinal 
inflammation are generated by activated phagocytes178.  To determine the capability of 
the TKNs to release agents in response to a physiologically relevant source of ROS, we 
compared the amount of intracellular dye released from dye-loaded TKNs in activated 
(ROS overproducing) versus non-activated phagocytes.  Macrophages were treated with 
TKNs loaded with 5-chloromethylfluorescein diacetate (CMFDA), washed of excess 
particles, and then activated with lipopolysaccharide (LPS).  CMFDA is activated by 
intracellular proteases; therefore, the cellular fluorescence of cells treated with CMFDA-
loaded TKNs (CMFDA-TKNs) will be proportional to the amount of CMFDA released 
from phagocytosed TKNs.  Figure 4.2.b shows that CMFDA-TKNs released CMFDA at 
an accelerated rate in response to ROS produced by activated macrophages.  For 
example, LPS-activated macrophages showed a greater than seven-fold increase in 
cellular fluorescence compared to non-activated macrophages.  This dramatic increase 
in cellular fluorescence was mitigated by treating LPS-activated macrophages with the 
ROS-scavenger TEMPOL (Figure 4.2.b), indicating that the amount of CMFDA released 




Figure 4.2.  PPADT is an ROS-sensitive polymer and nanoparticles formulated from it 
release their payloads in response to ROS produced by activated macrophages and 
inflamed colonic tissue.  (a) GPC traces of PPADT before (blue) and after exposure to KO2 
(green).  Incubating PPADT in acidic and basic environments (0.5 N HCl & 0.5 N NaOH) had no 
effect on the molecular weight of PPADT (coincident traces represented with blue line).  (b) 
Intracellular fluorescence of macrophages treated with CMFDA-loaded TKNs.  Results expressed 
as mean fluorescence ± standard error of the mean (s.e.m.) for n = 3 per group.  Statistical 
significance was determined by a one-way ANOVA using Bonferroni’s post hoc test (*p ≤ 0.05, 
**p ≤ 0.001).   
 
4.4.3. TKNs and not PLGA nanoparticles remain stable in intestinal fluids 
To evaluate the stability of both TKNs and particles made from the FDA 
approved material PLGA in the presence of digestive fluids, we incubated nanoparticles 
loaded with the dye Rhodmine in simulated gastric and intestinal fluids (GF and IF, 
respectively) prepared according to the recommendations found in US pharmacopoeia.  
During the course of the experiments we measured die release into the media.  As 
reflected by the data presented in Figure 4.3.a, which shows the percentages of 
encapsulated dye released into the medium in 4 h, PLGA nanoparticles released nearly 
10 X more rhodamine into the simulated fluids than did the TKNs.  After 4 h, the PLGA 
nanoparticles had released almost 25% and 10% of their contents in intestinal and 
gastric fluids, respectively.  Whereas TKNs released less than 4% of their contents over 





Figure 4.3.  TKNs remain stable in simulated gastric fluids, and when delivered orally, 
target encapsulated agents to inflamed intestinal. (a) Release rate of rohdamine from TKNs 
and PLGA nanoparticles in simulated gastric fluids.  Results depicted as mean % of encapsulated 
dye ± s.d. for n = 3 samples. (b)  Biodistribution of Cy3-tagged siRNA in the organs on day seven 
of mice treated with a daily gavage of Cy3siRNA-TKN s for 6 days (D: distal, M: medial, P: 
proximal). Fluorescent units (FU) per gram of tissues depicted as the mean ± s.d. for n = 3 mice 
per group (*p ≤ 0.05). 
 
4.4.4. Orally delivered siRNA-loaded TKNs target intestinal inflammation 
The stability of the TKNs to simulated GI fluids and their ability to release 
encapsulated agents, including siRNA in response to ROS, motivated us to determine if 
orally delivered TKNs could target siRNA to inflamed intestinal tissues.  Intestinal 
inflammation was induced in female C57BL/6 mice by replacing their drinking water on 
















day zero with a 3% solution of DSS179.  Starting on day zero, mice receiving either DSS 
or normal drinking water were given a daily oral gavage of TKNs loaded with a Cy3-
tagged scrambled siRNA (Cy3siRNA).  On day seven, the biodistribution of siRNA was 
measured by fluorescence.  Our results demonstrate that the TKNs can localize orally 
delivered siRNA to sites of intestinal inflammation (Figure 4.3.b).  For example, Figure 
4.3.b shows a greater than 3-fold increase in the amount of Cy3siRNA delivered to the 
distal and proximal sections of the colons of mice receiving DSS and Cy3siRNA-TKNs 
as compared to mice receiving normal water and treated with Cy3siRNA-TKNs.   
 
4.4.5. TNFα-TKNs reduce TNFα mRNA levels in activated macrophages 
Due to the essential role played by TNFα in the onset and persistence of 
intestinal inflammation180, we chose to treat mice suffering from DSS-induced colitis with 
a known TNFα-siRNA sequence181.  To demonstrate the ability of TNFα-TKNs to silence 
TNFα expression in the cells responsible for propagating the intestinal inflammatory 
response, we treated LPS-activated macrophages with TNFα-TKNs or appropriate 
controls.  Figure 4.4.a shows that treating LPS-activated macrophages with TNFα-TKNs 
resulted in a statistically significant reduction in TNFα production as compared to cells 
treated with PBS or TKNs loaded with a scrambled siRNA sequence (Sc-TNFα) (p ≤ 
0.05).  In addition, we discovered that TNFα-TKNs have an excellent cytotoxicity profile 
that is similar to nanoparticles formulated from the FDA approved material poly(lactic-co-
glycolic acid) (PLGA) (Appendix A).  These results show that TNFα-TKNs can protect 
siRNA from serum, deliver TNFα-siRNA in its active form, and decrease the expression 






4.4.6. TNFα-TKNs colonic mRNA of proinflammatory cytokines 
Based on these results, we hypothesized that orally administered TNFα-TKNs 
could silence TNFα expression in mice suffering from DSS-induced colitis, and thus 
inhibit intestinal inflammation.  To test our hypothesis, mice receiving DSS were given 
TNFα-siRNA or scrambled siRNA (2.3 mg siRNA/kg) encapsulated in TKNs via oral 
gavage once daily for five days.  Mice receiving DSS were also treated with free TNFα-
siRNA/DOTAP complexes (2.3 mg siRNA/kg/day) (TNFα-DOTAP) or PBS.  After seven 
days, the colonic mRNA levels of TNFα and other pro-inflammatory cytokines activated 
by TNFα, namely IL-6, IL-1, and IFN-γ, were analyzed by real-time PCR (RT-PCR).  As 
shown in Figure 4.4.b mice treated with TNFα-TKNs (2.3 mg siRNA/kg/day) experienced 
a dramatic ten-fold decrease in colonic TNFα mRNA (p ≤ 0.001).  Analysis of colonic IL-
6, IL-1, and IFN-γ, mRNA levels show that TNFα-TKNs also inhibited the activation of 
other pro-inflammatory signaling cascades (Appendix A).    
In order to determine if the increased stability of the TKNs (Appendix A) improves 
the efficacy of nanoparticle-mediated oral delivery of siRNA, we also treated mice 
receiving DSS with a daily gavage of TNFα-siRNA (2.3 mg siRNA/kg) encapsulated in 
size- and charge-matched PLGA (50:50) nanoparticles (TNFα-PLGA) prepared as 
described above for TNFα-TKNs.  Figure 4.4b shows that mice receiving DSS and 
treated with TNFα-PLGA did not experience a significant decrease in colonic TNFα-
mRNA. 
The high level of colonic TNFα suppression achieved by the TNFα-TKNs at a 
dose of 2.3 mg siRNA/kg/day motivated us to establish a minimum effective dose for 
TNFα-TKNs.  Mice receiving DSS were treated with a ten-fold lower dose of TNFα-TKNs 
(0.23 mg TNFα-siRNA/kg/day ) via a daily oral gavage for five days.  Figure 4.4.c 
illustrates that at this much lower dose TNFα-TKNs continue to produce a significant 
decrease in colonic TNFα mRNA (p ≤ 0.05) in mice receiving DSS.  In addition, this 
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approximately three-fold decrease in TNFα mRNA mitigated the activation of other 
proinflammatory signaling pathways that have been implicated in the development of 
UC, namely IL-6, IL-1, and IFN-γ (Figure 4.4.d).   To examine if the ROS-responsive 
properties of the TKNs play a significant role in their ability to treat intestinal 
inflammation, we compared the efficacy of TNFα-TKNs to (TNFα-siRNA)-loaded β-
glucan particles (TNFα-βGPs), which are designed to orally deliver siRNA to specialized 
cells in the intestines for systemic gene manipulation171.  Figure 4.4.c shows that mice 
receiving DSS and treated with TNFα-βGPs (0.23 mg siRNA/kg/day) did not experience 




















Figure 4.4.  TNFα-TKNs inhibit TNFα expression in vitro and reduce the colonic mRNA 
levels of proinflammatory cytokines in mice suffering from DSS-induced ulcerative colitis. 
(a) Extracellular TNFα mRNA levels as determined by ELISA.  Macrophages treated with 23.0 μg 
TNFα-siRNA/ml via TNFα-TKNs and activated with LPS expressed significantly less TNFα as 
compared to LPS-activated macrophages treated with PBS.  Results depicted as mean pg of 
TNFα per ml of media ± s.e.m. for n = 3 per treatment group. (b) TNFα mRNA levels in mice 
receiving DSS and treated scrambled- or TNFα-siRNA with 2.3 mg siRNA/kg/day via either 
TNFα-TKNs (n = 6), TNFα-PLGA (n = 5), Sc-TKNs (n = 5), siRNA-DOTAP (n = 6).  (c) TNFα 
mRNA levels in mice receiving DSS and treated with 0.23 mg TNFα-siRNA/kg/day via either 
TNFα-TKNs (n = 10) or TNFα-βGPs (n=10).  (d)  Colonic cytokine mRNA levels in mice receiving 
DSS and treated with either PBS or 0.23 mg TNFα-siRNA 0.23/kg/day via TNFα-TKNs (n = 10).  
Statistical differences in Figures a-d determined by a one-way ANOVA using Bonferroni’s post 
hoc test (*p ≤ 0.05, **p ≤ 0.001). Figures b-d determined by a one-way ANOVA using Bonferroni’s 
post hoc test (*p ≤ 0.05, **p ≤ 0.001). 
 
 
a               b 
c                     d 
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4.4.7. TNFα-TKNs reduce the clinical manifestation of Colitis 
Finally, we investigated if the reduction in colonic TNFα mRNA generated by 
TNFα-TKNs was sufficient to allay the clinical manifestations of DSS-induced UC.  Our 
results demonstrate that TNFα-TKNs protected mice from DSS-induced colitis as 
assessed by histological analysis, colonic myeloperoxidase (MPO)-activity, and weight 
loss (Appendix A).  For example, the colons of mice receiving DSS and treated with 
TNFα-siRNA (0.23 mg/kg/day) via TNFα-TKNs had  intact epitheliums, well defined crypt 
structures, and relatively low levels of neutrophil invasion (Figure 4.5.d).  Additionally, 
colonic MPO activity in mice receiving DSS and treated with TNFα-TKNs (0.23 mg 
siRNAkg/day) was markedly reduced (Figure 4.5.g).  Finally, as depicted in Figure 4, 
mice treated with TNFα-siRNA via TNFα-TKNs were significantly heavier after seven 
days than mice receiving DSS and other treatments.  In contrast, mice receiving DSS 
and treated with TNFα-PLGA, TNFα-βGPs, Sc-TKNs, TNFα-DOTAP, and TNFα-βGPs 
showed all of the characteristics of DSS-induced inflammation as measured by 
histology, high levels of MPO activity, and significant weight loss (Figure 4.5 & Appendix 






























































Figure 4.5.  Orally administered TNFα-TKNs protect mice from DSS-induced colitis.  (a)  
H&E-stained colon section from mice after seven days of receiving normal water and a daily oral 
gavage of PBS (20X).  (b-f) H&E-stained colon sections form DSS-treated mice given a daily 
gavage of one of the following:  (b) PBS, (c) Sc-TKNs (2.3 mg/kg), (d) TNFα-TKNs (0.23 mg/kg), 
(e) TNFα-PLGA (2.3 mg/kg), or (f) TNFα-βGPs (0.23 mg/kg) (20X).  (g) Colonic MPO activity.  
Results are expressed as mUnits of MPO activity per mg protein and error bars represent ± 
s.e.m.  Statistical significance was calculated using a one-way ANOVA and Bonferroni’s post hoc 
test (**p ≤ 0.05).  (h)  Time course of mouse body weight.  Mouse body weight was normalized as 
a percentage of day zero body weight.  Body weight depicted as the mean of each treatment 
group.  Error bars represent ± s.e.m.  Asterisk represents statistical significance from all other 
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4.5. Discussion  
Numerous controlled release devices such as pellets, capsules, tables and sub 
millimeter sized spheres have been used for decades to ferry therapeutics through the 
GI system and delivery drugs specifically to the colon182.  These devices are engineered 
to target the colon via various mechanisms, including pH changes, bacterial content, and 
residence time through the GI-system.  These mechanisms are organ specific and thus 
unable to target physical stimuli specific to diseased colons.  Furthermore, the 
macroscopic size of these carriers makes them susceptible to rapid GI clearance due to 
diarrhea, a common symptom of IBD182.  Although drug delivery platforms in the sub-
nanometer range have proven to have longer residence times in the GI systems of 
animals suffering from IBD, and are effective at delivering small molecules to treat 
intestinal inflammation, these nanoparticles systems are composed of polymers 
containing ester linkages, which are susceptible to enzymatic and hydrolytic cleavage in 
the gastrointestinal tract183-185.         
 
In this chapter, we describe a drug delivery platform that is able to target orally 
delivered siRNA to sites of diseased development via two distinct mechanisms.  First, 
TKNs remain stable in the GI tract, thus preventing delivery to healthy GI tissues.  
Second, TKNs degrade in the presence of ROS, which can be as much as 100 times 
greater at sites of intestinal inflammation.  Indeed, we have provided evidence that 
TKNs, and not nanoparticles formulated from ester-containing biomaterials, remain 
stable in fluids that resemble those of the GI system.  Furthermore, ROS-mediated 
release results and targeting studies demonstrate that, when delivered orally, TKNs 
localize the delivery of siRNA to inflamed intestinal tissues.   
Although it is unknown into which physiological compartment siRNA is released 
from the TKNs, based on our cell culture results, the pathophysiology of colitis, and the 
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formulation of TKNs,  we hypothesize that both extracellular and intracellular ROS can 
initiate the release of therapeutically viable siRNA.  Given the major source of 
inflammation-related ROS is produced by activated macrophages and neutrophils in the 
submucosal region of the colon, ROS-mediated damage to cellular luminal components 
such as tight junction proteins and membrane lipids is an exacerbating and persistent 
feature of colitis12,186.  Furthermore, oxidation events on proteoglycans that compose the 
intestinal mucosa have also been documented in patients suffering from ulcerative 
colitis14.  Based on these results, it is safe to assume that the dissemination of ROS 
away from the epithelium into the luminal compartment will results in TKNs degradation 
and subsequent siRNA release at locations distant from the epithelial surface.  In an 
attempt to increase the efficacy of siRNA released into the lumen, prior to encapsulation 
in nanoparticles, we complexed siRNA oligos with the cationic lipid DOTAP, and then 
loaded these siRNA-DOTAP complexes into nanoparticles.  Complexing siRNA with 
cationic species, such as DOTAP, enhances siRNA trasfection by increasing siRNA 
stability187, internalization188, mucosal transport189, and endosomal escape190,191.  Thus, 
at sites of intestinal inflammation, these DOTAP complexes are expected to act as a 
secondary delivery vehicle and thereby improve the efficacy of siRNA released from the 
TKNs in response to both intracellular and extracellular ROS.   
Another major luminal boundary to siRNA delivery is the layer of 155 µM thick 
mucus that covers the intestinal epithelium.  Although appearing homogeneous, the 
mucus layer covering the epithelium is actually stratified into regions of high-density near 
the epithelium, with pore sizes of less than 200nm, and a luminal low-density region, 
with pore sizes of greater than 1 µM192.  Given that particle that can penetrate the low 
density region of the mucus are cleared more slowly from the intestines, we engineered 
siRNA-loaded TKNs to have diameters of ~600 nm.  We hypothesized that this 
nanoparticle size would limit nonspecific uptake by enterocytes193, yet still allow for 
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binding to inflamed colonic mucosa194 and efficient uptake by phagocytes190,195, which 
are exposed to the luminal space at sites of severe inflammation 196.  Furthermore, 
incorporating DOTAP endows nanoparticles with a net positive surface charge 
(Appendix A), which is known to increase particle uptake by phagocytes195 and adhesion 
to the negatively charged intestinal mucosal surface197.  
Due to the low bioavailability of most orally administered drugs, oral 
administration is generally considered to be less toxic and safer than iv administration.  
Indeed, during the course of treatment, particles started to appear in the fecal matter of 
mice receiving formulation containing nanoparticles (data not shown).  Reported studies 
with orally delivered radio labeled polystyrene nanoparticles have shown that less than 
13% of orally delivered nanoparticles are actually taken up by intestinal tissues in 
healthy mice192.  Although we anticipate this percentage is greater in inflamed intestinal 
mucosa, we hypothesize that the majority of nanoparticles pass through the animal 
without delivering siRNA.  A discussion of strategies to improve the efficacy of the TKNs 
is provided in Chapter 6 of this thesis.  
  In another undocumented finding, after three days of therapy, the cages 
acquired the faint rotten egg odor that is distinctive of free thiols.  Although the polymer 
is synthesized from di-thiol monomers, the polymerization traps these terminal thiols in 
thioketal linkages, which eliminates their odor.  According to the reported mechanism for 
thioketal oxidation, PPADT degrades into acetone and the starting monomeric dithiol198.  
Thus, the faint odor of thiols in the animals’ excrement is an indirect sign of particle 
degradation and subsequent clearance of the degradation products from the animals.  
Although the free thiols produced upon polymer degradation could undergo disulfide 
exchange with native proteins, disulfides produced in the lumen are more likely to react 
with free thiols in the luminal environment and be cleared from the body.  Conversely, 
thiols are well-known scavengers of ROS, and thus the degradation products might also 
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be weakly anti-inflammatory.  Further studies will need to be done with radio labeled 
polymers to determine the clearance rate and exit point of the polymers degradation 
products and un-degraded particles.        
In this work, we performed a head-to-head comparison with another delivery 
vehicle reported to potentiate the oral delivery of siRNA, namely the β-glucan 
particles199.  It is not surprising that the TKNs outperformed the β-glucan particles, which 
require 4 days of pre-dosing before being effective.   Furthermore, β-glucan particles 
were designed to treat acute systemic inflammation, and thus are ill-suited to treat 
chronic diseases that are localized to a particular organ such as ulcerative colitis.  At the 
lowest dose examined in this work, 0.23 mg siRNA kg-1day-1, TKNs were able abrogate 
the effects of DSS-induced colitis.  These results suggest that orally delivered TKNs 
perform as well as current systemic delivery systems for siRNA that have been used to 
treat DSS-induced colitis, which required 2.5 mg siRNAkg-148h-1 to achieve a similar 
level of colonic gene suppression167.     
Oral administration represents the most convenient and cost-effective means to 
deliver siRNA to diseased intestinal tissues, and thus has the potential to significantly 
increase the patient population treated via siRNA-based therapeutics.  However, GI 
fluids, the intestinal mucosa, and cellular barriers to uptake represent significant 
obstacles for orally delivered siRNA.  In this chapter, we present evidence that TKNs 
have the chemical and physical properties needed to overcome these obstacles and 
provide a therapeutic level of gene silencing in inflamed intestinal tissues.  Indeed, 
elevated ROS levels are also associated with GI diseases that affect the proximal 
organs of the GI system, such as Crohn’s Disease (small-intestine), stomach cancer, H. 
pylori infections (stomach), and pancolitis (proximal and distal regions of large intestine).  
Given the non-organ specific delivery mechanism of the TKNs, we anticipate TKNs will 
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find numerous applications in the treatment of other intestinal diseases linked to 

























Chapter 5: NF-κB-inhibiting Poly-CAPE nanoparticles Block Drug 
Resistance and Potentiate the effect of CPT-11 
  
5.1. Abstract 
Activation of nuclear factor-κB (NF-κB) results in the expression of numerous 
prosurvival genes that block apoptosis, thus mitigating the efficacy of 
chemotherapeutics82.  Paradoxically, conventional therapeutics for cancer activate NF-
κB, and in doing so initiate drug resistance21.  Although adjuvant strategies that block 
NF-κB activation could potentiate the activity of chemotherapeutics in drug resistant 
tumors, clinical evidence suggests that current adjuvant strategies also increase 
apoptosis in non-malignant cells48.  In this chapter, we present a nanoparticle, 
formulated from a polymeric NF-κB-inhibiting prodrug, that can target the 
chemotherapeutic irinotecan (CPT-11) to solid tumors, and thus abrogates CPT-11-
induced drug resistance and inhibits tumor growth.  In order to maximize the amount of 
NF-κB inhibitor delivered to tumors, we synthesized a novel polymeric prodrug, termed 
PCAPE, that releases the NF-κB inhibitor caffeic acid phenethyl ester (CAPE) as its 
major degradation product.  Using a murine model of colitis-associated cancer200 (CAC), 
we demonstrated that when administered systemically, CPT-11-loaded PCAPE-
nanoparticles (CCNPs) are three times more effective than a cocktail of the free drugs at 
reducing both tumor multiplicity and tumor size.  Given the central role played by NF-κB 
activation in drug resistance and inflammatory diseases, we anticipate numerous 










5.2. Introduction   
Despite access to advanced chemotherapeutics, patients in the United States 
suffering from CAC, have a five-year survival rate of less than 20%77.  This extremely 
poor prognosis is due primarily to the poor clinical response of CAC to conventional 
chemotherapeutics.  CPT-11 is currently considered the most effective drug for the 
treatment of CAC.  Although CPT-11 is initially effective, most CAC tumors treated with 
CPT-11 develop resistance during the course of therapy25.  Numerous studies have 
shown that CPT-11 activates NF-κB, which results in the expression of prosurvival 
genes that attenuate apoptosis, and thus abrogate the efficacy of CPT-11.  For this 
reason, adjuvant strategies that inhibit NF-κB activation may potentiate the efficacy of 
CPT-11 on CAC tumors24,26,201.   
The NF-kB family of transcription factors is well established as regulators of 
genes that control immune and inflammatory function.  Recently, activation of NF-κB has 
been shown to stimulate cell growth and inhibit apoptosis in a number of cancer cell 
lines.  In its inactive form, NF-κB is sequestered in the cytoplasm by a family of NF-κB 
binding proteins called IκB.  In response to activating stimuli, including cytokines and 
DNA-damaging agents, IκB is phosphorylated by the IκB kinase complex (IKK), which 
leads to IκB ubiquitination and subsequent degradation by the proteosome.  The 
degradation of IκB liberates NF-κB allowing it to translocate to the nucleus, where it 
increases the expression of a variety of prosurvival genes, including Bcl-xL and survivin.  
In addition to inducing drug resistance, recent studies used a murine model of CAC to 
shown that NF-κB activation is necessary for tumorigenesis and tumor growth in CAC.  
These results are consistent with clinical data that indicate that NF-κB activation in the 
colons of patients suffering from colitis is an excellent predictor of CAC development.   
By binding topoisomerase I to DNA, CPT-11 generates irreversible damage to 
DNA during cell replication, causing cell cycle arrest and touching off a chain reaction of 
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pro-apoptotic signaling pathways202.  Although the exact mechanism by which the DNA 
damage caused by CPT-11 activates NF-κB is unknown, CPT-11-induced apoptosis 
results in an accumulation of reactive oxygen species (ROS), a known NF-κB activator, 
as well as the activation of IKK.  Several studies have demonstrated the ability of various 
NF-κB inhibitors to potentiate CPT-11 in colon cancer cell lines and preclinical studies of 
CRC22-24,201.  Although these studies achieved impressive levels of sporadic CRC tumor 
growth inhibition, they employed NF-κB inhibitors that either have toxicities that are likely 
to limit their clinical application, or have since been shown to be ineffective in human 
trials203,204.  Furthermore, since CAC tumors are known to have higher levels of 
constitutive NF-κB activation compared to sporadic CRC tumors, CAC tumors are more 
difficult to treat, and thus often do not respond to the same treatment regimen used to 
treat sporadic CRC69.   
NF-κB inhibitors should be non-toxic, effective, and clinically viable.  Numerous 
food-derived polyphenols are effective inhibitors of NF-κB, pharmacologically safe, and 
currently marketed as food supplements.  Caffeic acid phenethyl ester (CAPE), a 
biologically active ingredient in bee’s wax, is a well-known inhibitor of NF-κB that has 
demonstrated efficacy in numerous animal models of inflammatory 
diseases106,124,128,131,140,152,205-207.  Studies have demonstrated that, as a standalone 
therapeutic, CAPE inhibits the proliferation of various cancer cell lines by inhibiting NF-
κB, but is innocuous to normal cells.  CAPE has also been shown to be tumor 
suppressive in preclinical studies; however, its efficacy as an adjuvant therapeutic has 
yet to be examined in vivo.   
Despite CAPE’s numerous beneficial properties, its relatively moderate activity 
coupled with its extremely poor water solubility make it difficult to achieve and maintain 
therapeutic concentrations in the blood compartment.  Furthermore, it is likely that the 
combination of CAPE and CPT-11 will suffer from a universal problem plaguing all NF-
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κB inhibitor/chemotherapy cocktails—the increased toxicity cause by inhibiting NF-κB in 
non-malignant cell types that are susceptible to chemotherapeutics.   
Our goal was to develop a robust delivery platform that could overcome the 
above limitations by targeting therapeutic concentrations of CAPE and CPT-11 to tumors. 
Prior to selection of materials and delivery vehicle design, we defined performance 
parameters applicable to almost any solid malignancy, not just CAC.  These 
requirements included the ability to target solid tumors, simultaneously deliver CAPE 
and CPT-11, resist hepatic clearance, and sustain a therapeutic concentration of the 
therapeutics in the tumor microenviroment between doses.  Given their ability to 
passively accumulate in tumors208, deliver multiple therapeutics209, and serve as 
controlled release drug depots210, polymeric nanoparticle are an attractive platform for 
the delivery of CAPE and CPT-11.  However, the high doses of CAPE (70 - 500 mg-1 kg-1 
wk-1) required to inhibit NF-κB in vivo precluded the use of nanoparticle formulations that 
require an excessive amount of polymer to form a stable matrix around the drug.   
 In order to formulate hyper-loaded nanoparticles that can deliver the quantity of 
CAPE reported to be required to inhibit NF-κB, we synthesized a polymeric CAPE 
prodrug (PCAPE) that releases CAPE as its major degradation product.  Particles 
formulated from PCAPE, termed CAPE nanoparticles (CNPs), are composed of 65 % 
CAPE and can be loaded with CPT-11 using standard protocols.  In this chapter, the 
ability of the NF-κB inhibitor CAPE to improve the efficacy of CPT-11 on HT-29 cancer 
cells was examined and a mechanism for improved efficacy suggested.  Polymers that 
incorporate the NF-κB inhibitor CAPE into their backbone were synthesized and 
characterized.  CPT-11-loaded nanoparticles formulated from PCAPE (CCNPs) were 
generated and characterized.  Finally, the efficacy of CCNPs versus appropriate controls 




5.3. Materials and Methods: 
Unless stated otherwise all chemicals were obtained from Sigma. 
5.3.1. Synthesis of caffeic acid phenethyl ester (CAPE) (6) 
To a solution of caffeic acid (4) (1.98 g) in 25 ml of hexamethylphosphoramide 
(HMPA), 2.28 ml of 25% NaOH was added. After stirring for 1 h, a solution of β –
bromoethylbenzene (5) (5.7 ml) in 10 ml HMPA was added dropwise with a separatory 
funnel and the solution was stirred for 52 h at rt. The reaction mixture was then poured 
into ice water (50 ml), and the product was extracted with diethylether (2350 ml). The 
ether extract was washed successively with 1 N HCl (20 ml) and water (20 ml), dried 
over MgSO4 (10—15 g), and evaporated under vacuum. The product dissolved in ether 
was chromatographed on a silica gel column (150 g), eluted with CHCl3 and then with 
increasing proportions of ethyl acetate. The fraction eluted with 30% ethyl acetate 
contained the desired product.  
 
5.3.2. Synthesis of (CAPE-DPA) (8):   
CAPE (6), pyridine, and a catalytic amount of DMAP were added to DMF (ml) 
and stirred at 0°C.  After 1 h, penenoic anhydride (7) was added drop-wise to the stirred 
solution.  The reaction mixture was allowed to come to r.t. and stirred overnight before 
being reduced to 25% of its original volume via rotary evaporation.  The concentrated 
reaction mixture was then poured into a mixture of ice and sodium bicarbonate and 
extracted 3 X with DCM.  The combined organic phases were washed with water and 
dried over Na2SO4.  The crude product was evaporated onto silica gel and purified via 
flash silica gel chromatography by eluting with hexanes and then with increasing 





5.3.3. Synthesis of PCAPE (9):   
CAPE-DPA (8)  and 1st generation Grubbs Catalyst were added neat to a 15 ml 
flask equipped with a condenser and vacuum adapter and stirred immediately at 70°C 
under light vacuum.  After 6 h, the reaction mixture became too viscous to stir, at which 
time 0.5 ml of degassed distilled toluene were added to the flask to liberate the stir bar.  
After the initial addition of toluene, 0.5 ml of toluene were added every 6 h to replace the 
toluene removed by the vacuum.  After 18 h, the reaction was added to methanol and 
and cooled to -20°C.  Once the polymer had precipitated from the mixture, the methanol, 
unreacted monomers, and Grubbs Catalyst were decanted and the remaining 
precipitated polymer was concentrated under vacuum.   
 
5.3.4. CAPE nanoparticle formulation 
Nanoparticle coated in the pluronic F-127 were formulated via a typical solvent 
displacement procedure.  A solution of tetrahydrofurane (THF) containing 1.0 % CAPE 
and  0.15% CPT-11 (w/v) was slowly added to 20 equivalents of rapidly stirred pH 6.5 
PBS via a syringe pump to form a semi-stable emulsion.  After 30 min of stirring, the 
emulsion was then transferred to a 250 ml flask and the THF was removed via rotary 
evaporation under reduced pressure.  Next, the flask was transferred to a stir plate and 
the solution containing the now hardened particles was stirred at a moderate rate while 
an equal volume of a 0.2% solution of F-127 in PBS (pH7.4) was slowly poured into the 
particle solution.  The solution was allowed to stir for an hour to allow the pluronic to 
adsorb to the surface of the particles. The particles were then transferred to ultra 
centrifuge tubes (Beckman Coulter), and centrifuged at 42,000 RPM and 4°C for 30 min.  
The supernatant was then decanted and the particles were resuspended in PBS (pH 
7.4) and re-centrifuged as before.  After the second centrifugation, the particles were 
47 
 
resuspended in a 0.01% solution of glucose in DI water, flash frozen in liquid nitrogen, 
and then lyophilized overnight (Labconco).  The particles were recovered from the 
lyophilizer as a gray powder and stored at – 20°C.  Empty nanoparticles were prepared 
as described above with the exception of the CPT-11 in the organic phase.  Particle size 
was measured via dynamic light scattering (Brookhaven Instruments Corporation), and 
morphology was assessed via SEM (Hitachi).                 
 
5.3.5. Colitis associated cancer tumor induction and treatment. 
CAC was induced as previously described, with some modifications 211. C57BL/6 
Mice (Jackson Laboratories) were intraperitoneally injected with AOM (10 mg kg-1) and 
maintained on regular diet and water for 7 days. The mice were then subjected to 3 
cycles of DSS treatment, in which each cycle consisted of 2.5% DSS for 7 days followed 
by a 14-day recovery period with regular water.  After the final recovery period, mice 
received four weekly intravenous (iv) tail vein injections containing 200 µl of either a 10% 
solution of ethanol in PBS (v/v) or a 10% solution of ethanol in PBS containing one of the 
following therapeutics:  empty CNPs (62.8 mg kg-1 wk-1), unencapsulated CPT-11 (8.0 
mg kg-1 wk-1) and unencapsulated CAPE (40.8 mg kg-1 wk-1), CNPs loaded with a “low” 
dose of CPT-11 (62.8  mg kg-1 wk-1 of particles containing 2.0 mg kg-1 wk-1 CPT-11), and 
CNPs loaded with a “high” dose of CPT-11 (62.8 mg kg-1 wk-1 of particles containing 8.0 
mg kg-1 wk-1 CPT-11).  Two weeks after the final injection, the mice were sacrificed and 
the colon tissues were taken for further analysis.   
 
5.3.6.  Immunofluorescence 
HT-29 cells were seeded in 8-well glass chamber slides (Lab-Tek™, Thermo 
Scientific) at 3.0 X 105 cells ml-1 in media prepared as described above.  After 48 h, cells 
received media containing either 80 µM CPT-11, 80 µM CPT-11 and 80 µM CAPE, or 
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DMSO.  Cells were treated for a total of 4 h, and then washed 3 X with 0.01% Tween in 
TBS (0.01% TBST) and incubated with a 4% solution of paraformaldehyde in PBS for 20 
min.  After 20 min, the cell were washed 3 X with 0.01% TBST before being incubated in 
1% TBST at 37°C for 30 min.  The slides were then allowed to cool for 10 minutes 
before being washed 3X with 0.01% TBST and incubated in Immunohistochemistry 
blocking buffer (Bethyl Labs INC.) for 30 min.  The blocking buffer was removed via 
aspiration, and anti-rabbit primary antibodies suspended in primary antibody dilution 
buffer (Bethyl Labs INC.) were added directly to the cells.  After 1 h, the primary antibody 
solution was removed, and the cells were washed 3X with 0.01% TBST, before being 
incubated at r.t. with primary antibody dilution buffer containing a fluorescent goat anti-
rabbit antibody.  After 30 min, the secondary antibody solution was removed from the 
cells, and the cells were washed 3X with 0.01% TBST.  The medium chamber was then 
removed from each slide and a small amount of VECTASHIELD mounting medium with 
DAPI (Vector Laboratories) was added to each well before a cover slip was placed over 
the slide and sealed with Laque Brillance Extreme (Coco Chanel).   Images were 
acquired using an LSM 700 laser scanning confocal microscope (Carl Zeiss Micro 
Imaging) running Zen image acquisition software (Carl Zeiss Micro Imaging). 
     
5.3.7. Immunohistochemistry. 
5-μm paraffin-embedded tissue sections were deparaffinized in xylene, incubated 
in 3% hydrogen peroxide in methanol for 30 minutes, rehydrated in decreasing 
concentrations of ethanol (100, 95, 70%), and then treated with 10 mM sodium citrate 
buffer (pH 6.0) containing 0.05% Tween 20 at 120°C for 10 minutes in a pressure 
cooker. Sections were blocked with 2% nonfat dry milk and 0.01% Tween 20 in PBS for 
1 hour at 37°C, and then incubated with anti-Ki67 (Novocastra) overnight at 4°C. After 
washes with PBS containing 0.01% Tween 20, sections were treated with appropriate 
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biotinylated secondary antibodies for 30 minutes at 37°C, and color development was 
performed using the Vectastain ABC kit (Vector Laboratories). Sections were then 
counterstained with hematoxylin, dehydrated, and coverslipped. Images were acquired 
using a Zeiss Axioskop 2 plus microscope (Carl Zeiss Micro Imaging) equipped with an 
AxioCam MRc5 CCD camera (Carl Zeiss USA). 
 
5.3.8. Real time RT-PCR 
Total RNA was extracted from mouse colons using TRIzol (Invitrogen).  A 
reverse transcription (RT) reaction was performed on 2 µg of each sample and an oligo-
dT primer, using a RETROscript® System (Ambion Inc.).  Next, 10 ng of reverse-
transcribed cDNA, 400 nM of gene-specific primers, and the iQ SYBR Green Suppermix 
(Biorad) was amplified at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s and 60°C for 1 min.  The 36B4 expression levels were used as reference, 
and fold-induction was calculated by the Ct method as follows: ∆∆CT=(Ct Target – Ct 
36B4)DSS+Treatment - (Ct Target – Ct 36B4)DSS+ PBS.  Thus producing results normalized against 
mice receiving DSS and treated with PBS.  The final data were then derived from 2-∆∆CT.  
The primers used were designed using the Primer Express Program (Applied 
Biosystems) and were as follows: TNFα sense 5’-AGG CTG CCC CGA CTA CGT-3’ 
antisense 5’-GAC TTT CTC CTG GTA TGA GAT AGC AAA-3’; IL-1β sense 5’-TCG CTC 
AGG GTC ACA AGA AA-3’ antisense 5’-CAT CAG AGG CAA GGA GGA AAA C-3’; IL-6 
sense 5’-ACA AGT CGG AGG CTT AAT TAC ACA T-3’ antisense 5’-TTG CCA TTG 
CAC AAC TCT TTT C-3’; IFN-γ sense 5’-CAG CAA CAG CAA GGC GAA A -3’ 









5.4.1. CAPE potentiates the efficacy of CPT-11 
In order to demonstrate the ability of CAPE to induce chemo-sensitivity in the 
drug resistant cell line HT-29, we treated HT-29 cells with CPT-11, CAPE, or the 
combined therapeutics then assayed the cells for the surface presentation of 
phosphatidylserine, a known marker for apoptosis, via FACS.   
 
       
Figure 5.1.  CAPE potentiates the activity of CPT-11.  HT-29 cells were treated with various 
amounts of CAPE and CPT-11 for 48 h then stained with annexin V and analyzed via FACS.  
Results presented as median percentage of annexin V positive cells ± s.d. for n = 4 replicates per 
group.  Statistical differences determined by one-way ANOVA using Bonferroni’s post hoc test (*p 
≤ 0.05).  
 
Quantification of apoptosis in cells treated with either CAPE or CPT-11 (Figure 
5.1) showed that there was no significant difference in apoptosis between the 3 doses of 
CAPE, and only a moderate increase in apoptosis when the CPT-11 concentration was 
increased from 25 µM to 50 µM.  However, further increasing the CPT-11 concentration 
from 50 µM to 100 µM had no significant affect on apoptosis.  Importantly, at each one of 






























in apoptosis that correlated with CAPE concentration.  For example, at 50 µM CPT-11, 
the addition of 50 and 100 µM CAPE resulted in a 2.2 and 3.5-fold increased in 
apoptosis over compared to cells treated with CPT-11 only.     
Given that CPT-11 induces drug resistance by activating NF-κB, we assessed 
nuclear NF-κB levels in HT-29 cells treated with CPT-11, CAPE, or the combined 
therapeutics.  Figure 5.2 shows the fold increase in nuclear NF-κB over the level of 
nuclear NF-κB in untreated cells. (e.g. a value of 1.0 represents no increase in NF-κB as 
compared to the untreated cells)  Cells treated with CPT-11 at 50 and 100 µM 
experienced a 1.8 and  3-fold increase in nuclear NF-κB, respectively.     
 
 
Figure 5.2.  CAPE reduces CPT-11-induced NF-κB activation in HT-29 cells. HT-29 cells 
were treated with various amounts of CAPE and CPT-11 for 4 h then analyzed for nuclear NF-κB 
content via ELISA.  Results presented as median fold increase in nuclear NF-κB over nuclear NF-
κB levels of untreated cells ± s.e.m. for n = 4 replicates per group.  Statistical differences 
determined by a one-way ANOVA using Bonferroni’s post hoc test (*p ≤ 0.05).  
 
However, at both of the CPT-11 concentrations examined, adding CAPE to the regimen 
resulted in a significant decrease in the amount of nuclear NF-κB.  For example, adding 
CAPE at a concentration of 25 and 50 µM to cells treated with CPT-11 at 100 µM, 
resulted in a 30% and 43% decrease in nuclear NF-κB, respectively.  
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In order to confirm the results obtained by ELISA, NF-κB nuclear localization was 
visualized in HT-29 cells that had been treated with CPT-11 alone and in combination 
with CAPE.  In cells treated with CPT-11 (50 µM), NF-κB was localized to the nucleus as 
indicated by the co-localization of the signal for NF-kB (Figure 5.3, panel a & c) and 
nuclear DNA (Figure 5.3, panel b & c).  However, HT-29 cells treated with CPT-11 (50 
µM) and CAPE (100µM) showed cytoplasmic sequestration of NF-kB (Figure 5.3, panel 
d & f), indicative of NF-κB inhibition. 
 
 
Figure 5.3.  CAPE decreases CPT-11-mediated nuclear localization of the NF-κB subunit 
p65:  HT-29 cells treated with CPT-11 (50µM) alone (upper panels) or in conjunction with CAPE 
(100 µM) (lower panels) for 4 h were immunostained for the p65 subunit of NF-κB (red) and for 
genomic DNA (blue) then imaged by confocal microscopy.  (a – c) Confocal microscopy clearly 
indicates that CPT-11 initiates the nuclear localization of NF-κB. (d – f) In contrast, NF-κB 
remained sequestered in the cytosol of cells treated with CPT-11 and the NF-κB inhibitor CAPE. 
 
5.4.2. PCAPE polymers are designed to release CAPE upon degradation  
Given CAPE’s relatively low activity, we decided to maximize CAPE 
encapsulation within nanoparticles by synthesizing a polymer that contained CAPE in its 
backbone.  PCAPE was synthesized via the synthetic pathway shown in Figure 5.4.a 
         a                                    b                                   c 
         d                                     e                                   f 
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This synthetic strategy produced CAPE polymers with molecular weights Mw ~ 7.5 kDa 






Figure 5.4.  Synthesis of PCAPE and characterization of CNPs. (a) (i)  hexamethyl-
phosphoramide (HMPA), NaOH, 54 h; (ii) pyridine, DMAP, DMF 1h; (iii) Grubb’s Catalyst (neat) 
1h, toluene 20 h. (b)  SEM image of CNPs (c) % Irinotecan (CPT-11) released from CCNPs as a 
function of time.  Results represented as the % of encapsulated irinotecan released ± s.e.m. for n 




















PCAPE was used to formulate CNPs, and CCNPs via a solvent displacement 
method (Figure 5.4.b).  In order to verify the deposition of pluronic F-127 on the surface 
of the particles, CNPs were made with and without F-127 and sized via DLS before 
lyophilization.  CNPs coated with F-127 had an average diameter of ~180 nm, and CNPs 
without had an average diameter of 130 nm.  The distribution of both particle formulation 
were symmetric about the mean, indicating that the increase in size was not the result of 
particle aggregation212,213.  Irinotecan (CPT-11) release studies (Figure 5.4.c) performed 
in PBS pH 7.4 show that 12 % CCNPs (12 wt % CPT-11) release their payloads over a 
14 day period, with an approximate half-life of 2.3 days.   
 
5.4.3. CCNPs reduce tumor multiplicity and tumor size 
To assess the efficacy of CCNPs we treated mice bearing AOM-induced tumors 
with CCNPs and appropriate controls.  Prior to treatment, colon tumor formation was 
verified via colonoscopy as shown in Appendix B.  Tumor-bearing mice received one of 
the following therapies via weekly tail vein injection: CNPs containing either 4 or 12 % 
CPT-11 as a percentage of total particle weight (4% CCNP: 3.0 mg kg-1 wk-1 CPT-11; or  
12% CCNP:  9.0 mg kg-1 wk-1  CPT-11), empty CNPs (CNPs), a solution containing the 
free CAPE and CPT-11 (CAPE + CPT-11), or a solution of ethanol in PBS (Vehicle).  It 
should be noted that each formulation containing CAPE in either its free or polymeric 
form (i.e. 4% CCNPs, 12% CCNPs, CNPs, CAPE + CPT-11) contained the same 
amount of CAPE.  As shown in Figure 5.5, both 4% CCNPs and 12% CCNPs elicited a 
significant reduction in colonic tumor number and tumor load as compared to vehicle 
treated mice.  Mice receiving 12% CCNP had less than half as many tumors as vehicle 
treated mice and over 40% fewer tumors than mice treated with a solution containing an 
equivalent amount of free CAPE and CPT-11 (i.e. CAPE + CPT-11). Although the free 
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drugs were able to achieve a significant reduction in tumor load compared to vehicle 
treated animals, the free drugs did not significantly decrease tumor multiplicity.  
Importantly, although mice treated with 4% CCNPs were administered 1/3 the CPT-11 
contained in the free drug formulation, 4% CCNPs generated a significant reduction in 
both tumor load and tumor number.     
          
 
Figure 5.5.  CPT-11 loaded-CNPs reduce both the multiplicity and size of tumors in mice 
bearing AOM-induced colon tumors.  Mice bearing AOM-initiated colon tumors were treated 
with either empty CNP, a solution of free CAPE and CPT-11 (9.0 mg kg-1 wk-1 CPT-11), 4% 
CCNPs (3.0 mg kg-1 wk-1 CPT-11), or 12% CCNPs (9.0 mg kg-1 wk-1 CPT-11) via tail vein 
injection for 4 weeks. (a) The number of tumors present in the colons of mice bearing AOM-
induced tumors after 4 weeks of treatment.  Results depicted as mean tumor number per animal 
± s.e.m. for n = 6 mice per treatment group.  (b)  Average tumor load per animal.  Tumor load is 
calculated as the sum of the volumes of the tumors in a single animal. Results depicted as mean 
tumor load per animal ± s.e.m. for n = 6 mice per treatment group.  Statistical differences in 
Figures a-d determined by a one-way ANOVA using Bonferroni’s post hoc test (*p ≤ 0.05, **p ≤ 
0.01). 
   
Figure 5.6 displays representative photographic images of colons taken from a 
tumor-bearing mouse on the initial day of treatment (i.e. T-day 0) and images taken from 
the colons of tumor-bearing mice after receiving 4 weeks of treatment (i.e. T-day 28).  As 
  a                                                         b 
56 
 
shown in Figure 5.6.a, and in accordance with cited literature, the model of CAC used in 
this work generated clumps of tumors primarily in the distal and medial portions of the 
colon214.  After 4 weeks, the colons of vehicle treated mice were festooned with tumors 
(Figure 5.6.b).  
  
Figure 5.6.  Representative photographic images of tumor bearing colons taken from mice 
before and after 4 weeks of treatment. (a) before receiving treatment; (b) vehicle treated colon 
after 4 weeks; (c) CNP treated colon after 4 weeks; (d) free CAPE and free CPT-11 treated colon 
after 4 weeks (e) 4% CCNPs treated colon after 4 weeks; (f) 12% CCNPs treated colon after 12 
weeks. Colons treated with 12% CCNPs closely resembled the colons from mice receiving no 
therapy on the first day of treatment, (i.e.T-Day: 0) and had markedly fewer tumors than mice 




However, the colons of mice treated with 12% CCNPs closely resembled the colons 
from mice receiving no therapy on the first day of treatment, (i.e.T-Day: 0) and had 
markedly fewer tumors than mice receiving other treatments.   
   
5.4.5. CNPs and CCNPs inhibit NF-κB activation in tumors 
In an effort to elucidate the mechanisms through which the encapsulation of 
CPT-11 in CNPs improves the efficacy of the combination of CAPE and CPT-11, we 
assessed the concentration of nuclear NF-κB in tumor samples taken from mice treated 
as described above. Total nuclear protein was isolated from tumor samples and assayed 
for NF-κB content via ELISA.  Results in Figure 5.7 represent nuclear NF-κB 
concentration relative to the nuclear NF-κB concentration of vehicle treated mice.  
Tumors from animals treated with CNP, 4% CCNPs, and 12% CCNPs had significantly 
lower levels of nuclear NF-κB as compared to animals treated with the vehicle or the free 
drugs.  Interestingly, animals treated with a solution of CAPE and CPT-11 had 

































Figure 5.7.  CNPs suppress NF-κB activation in AOM-induced tumors.  Mice bearing AOM-
initiated colon tumors were treated with either empty CNP, a solution of free CAPE and CPT-11 
(9.0 mg kg-1 wk-1 CPT-11), 4% CCNPs (3.0 mg kg-1 wk-1 CPT-11), or 12% CCNPs (9.0 mg kg-1 
wk-1 CPT-11) via tail vein injection. Relative nuclear concentration of the p65 subunit of NF-κB 
was determined via ELISA.  Results depicted as the  mean relative NF-κB concentration per 
mouse ± s.e.m. for n=6 mice.  Statistical differences determined by a one-way ANOVA using 
Bonferroni’s post hoc test (*p ≤ 0.05). 
 
5.4.6. CCNPs deplete tumorigenic and drug resistance mRNA  
The nuclear localization of NF-κB results in the expression of numerous 
proinflammatory and prosurvival genes that induce tumor proliferation, metastasis and 
thwart the activity of apoptosis-inducing chemotherapeutics, including CPT-11.  We 
performed qPCR to quantify the tumor mRNA levels of genes known to induce cancer 
proliferation and drug resistance.  Tumors from animals treated with both 4% and 12% 
CCNPs had significantly lower proinflammatory mRNA levels than mice treated with the 
vehicle or a solution of the free drugs.  The results for cytokine mRNA levels were 
echoed in the analysis of prosurvival mRNA levels.  These results show that only 
formulations containing nanoparticles (i.e. CNPs, 4% CCNP, and 12% CCNP) 
significantly reduced both Bcl-xL and survivin mRNA compared to vehicle treated mice.  
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Tumor survivin mRNAs were 65% and 70 % lower in mice treated with 12% CCNPs 
compared to mice treated with the vehicle or the free drugs, respectively.  Interestingly, 
the addition of free CAPE was unable to reduce the mRNA levels of these pro-
tumorgenic  and prosurvival genes.   
   
Figure 5.8.  CCNPs reduce the tumor mRNA levels of gene known to promote 
tumorigenesis and drug resistance.  Mice bearing AOM-initiated colon tumors were treated 
with either empty CNP, a solution of free CAPE and CPT-11 (9.0 mg kg-1 wk-1 CPT-11), 4% 
CCNPs (3.0 mg kg-1 wk-1 CPT-11), or 12% CCNPs (9.0 mg kg-1 wk-1 CPT-11) via tail vein 
injection. (a - d)  Tumor mRNA levels for various genes up regulated by NF-κB activation that are 
known to promote tumorigenesis (i.e. TNF α and IL-1) and drug resistance (i.e. Bcl-xL and 
survivin). Results depicted as mean mRNA level ± s.e.m. for n = 6 mice per treatment group.  
Statistical differences in Figures a - d determined by a one-way ANOVA using Bonferroni’s post 
hoc test (*p ≤ 0.05). 
a                                                   b 
c     d 
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5.4.7. CNP nanoparticles passively accumulate in AOM-induced tumors 
Mice bearing AOM-induced tumors were administered CNPs loaded with the 
near-infrared dye IR-780 (CNP-780) or free IR-780.  After 48 h, the colons of these mice 
were harvested and analyzed for fluorescence.  Qualitative analysis of the fluorescent 
images taken of colons treated with CNP-780 and IR-780 shows that the colons from 
animals treated with CNP-780 (Figure 5.9. a, left panel) produce considerably more 
fluorescent signal than the colons taken from animals treated with the free dye (Figure 
5.9 a, right panel).  Furthermore, the colons of animals treated with CNP-780 exhibit 
punctuate high intensity fluorescence that is coincidental with sites of tumor 
development.  Integration of the fluorescent intensities of the colons indicate a more than 
15-fold increase in colonic fluorescence in mice treated with CNP-780 as compared to 
those treated with free IR-780.  Analysis of the other organs typically affected by 
chemotherapeutics (Figure 5.9.c & d) revealed relatively low levels of fluorescent 

































Figure 5.9.  CNPs localize the delivery of encapsulated agents to AOM-induced tumors.  
Mice bearing AOM-initiated colon tumors were treated with either CNPs loaded with the near-IR 
dye IR-780 (CNP-780) or an equivalent amount of free IR-780.  After 48 h, the colons of these 
animals were analyzed for fluorescence.  (a)  Fluorescent imaging of colons bearing AOM-
induced tumors and treated with CNP-780 (left) and free IR-780 (right).  (b)  Integration of 
fluorescent intensities of the colons pictured in panel a.  Colons treated with CPT-780 
experienced a nearly 15-fold increase in fluorescence compared to animals treated with IR 780.  
Results depicted as average fluorescence ± s.e.m. for n = 3 samples.  Statistical differences in 
panel b determined by student t-test (*p ≤ 0.01). (c) Representative image sowing relative 




NF-κB activation has been shown to be the principle mechanism for drug 
resistance in many different tumor cells lines and primary tumor samples80,215.  Ironically, 
many anticancer agents that induce apoptosis, such as CPT-11, also activate NF-κB, 
      a                    b 
      c       d 
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and in so doing deplete their own efficacy22,23. Numerous cell culture and preclinical 
studies have demonstrated that inhibiting NF-κB potentiates the efficacy of CPT-11.  
Despite the convincing evidence describing the synergy between NF-κB inhibition and 
CPT-11 in the treatment of CRC, there has yet to be a successful clinical trial that has 
used an NF-κB inhibitor in concert with CPT-11 to treat CRC.   
Clinically viable NF-κB inhibitors for adjuvant therapy must walk the fine line of 
being safe, yet effective, a task that is made all the more difficult when administered in 
combination with a chemotherapeutic.  Based on our desire to minimize the toxicity of 
the combined therapy, we selected the food-derived flavonoid CAPE because of its 
proven NF-κB inhibiting capability in tumors140,216-222, low toxicity223-227, and mechanistic 
synergy with CPT-11.  Although the exact pathways through which CAPE inhibits NF-κB 
have yet to be elucidated, structure-activity studies indicated that CAPE inhibits NF-κB 
though the generic scavenging of ROS as well as specifically inhibiting the activation of 
IKK228-232.  Studies performed on numerous cancer cell lines have demonstrated that 
increased ROS production and IKK activation are the pathways through which CPT-11 is 
known to activate NF-κB.  For this reason, CAPE is mechanistically well-suited to 
potentiate CPT-11 .     
Our results confirm that CAPE potentiates CPT-11-induced apoptosis of CPT-11 
resistant colon HT-29 cancer line.  For example, when used in tandem, at 50 µM each, 
(100 µM total), the combination of CAPE and CPT-11 induced as much apoptosis as 
CPT-11 at a dose of 100 µM.  Thus, by incorporating CAPE in the therapeutic regimen, it 
is possible to dramatically reduce the concentration of CPT-11 (the more toxic 
compound) without any loss of efficacy.  This result is surprising considering that at 50 
µM CAPE has almost no discernable toxicity.   Furthermore, at a CAPE concentration of 
50 µM, increasing the CPT-11 concentration from 50 µM to 100 µM had no significant 
effect on apoptosis.  Paradoxically, at 50 µM CPT-11, increasing the concentration of 
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CAPE from 50 µM to 100 µM resulted in a significant increase in apoptosis.  Together, 
these results demonstrate that CAPE potentiates the activity of CPT-11.  To identify the 
mechanism responsible for the CAPE/CPT-11 synergy, we performed 
immunofluorescence staining for NF-κB and measured the nuclear NF-κB levels in HT-
29 cells treated with the individual drugs and multiple combinations thereof.  The results 
of these studies confirmed our hypothesis that CAPE is capable of inhibiting CPT-11-
induced NF-κB activation.  Furthermore, these results suggest that CAPE’s ability to 
potentiate apoptosis is a result of its ability to block NF-κB activation—the primary 
mechanism of drug resistance.      
It is well-documented that sub 200nm particles can passively accumulate in the 
tumor microenviroment, and thus increase the efficacy of encapsulated 
chemotherapeutics.  CNPs were formulated using a solvent displacement protocol that 
produced ~180 nm particles.  In order to further increase their circulation time, and thus 
the probability that the particles accumulate in a tumor, we coated the CCNPs and CNPs 
with the amphiphilic pluronic F-127.  F-127 has been shown to self-assemble on the 
surface of hydrophobic particles, thus forming a hydrophilic corona that increases 
particle circulation time by decreasing particle opsonization and hepatic clearance233-236.  
Indeed, 48 h after administration, CNPs dramatically increase the amount of IR-780 dye 
retained in AOM-induced tumors.  Furthermore, CNPs delivered considerably more dye 
to the colon as compared to the heart, lungs, kidney, and spleen, suggesting that CNPs 
can reduce CPT-11-induced toxicity in these organs.  Although a significant portion of 
the particles accumulated in the liver, integration of the fluorescent intensities of the liver 
revealed that the fluorescent signal concentration in the liver is an order of magnitude 
less than the signal concentration in the colonic tumors.  Interestingly, at 1/10 to 1/5 of 
the doses that have been reported to inhibit NF-κB activation tumors, CAPE has been 
shown to attenuate chemotherapy induced hepatotoxicity and toxicity in other organs225-
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227,237-240. These studies attributed CAPE’s hepato-protective effect to CAPE’s ability to 
scavenge ROS and not the inhibition of NF-κB.  Therefore, maintaining a low non-NF-
κB-inhibiting hepatic concentration of CAPE could reduce the toxicity of CPT-11 in the 
liver.    
In order to demonstrate the efficacy of CCNPs in a preclinical tumor model, we 
treated mice bearing AOM-induced tumors with CCNPs and appropriate controls.  Our 
results demonstrate that CCNPs were able to significantly reduce tumor multiplicity and 
the tumor load in mice bearing AOM-induced tumors.  Importantly, at a three-fold lower 
dose of CPT-11, 4% CCNPs were more effective than the combination of free CPT-11 
and CAPE at reducing tumor multiplicity and equally effective as the free drugs at 
inhibiting tumor growth.  Analysis of tumor NF-κB activation levels revealed that mice 
treated with CNPs, 4% CCNPs, and 12 % CCNPs had significantly lower levels of tumor 
NF-κB activation compared to mice treated with the free drugs, suggesting that the 
superior efficacy of the CCNPs is a result of their ability to block CPT-11-induced NF-κB 
activation.  Quantitative PCR analysis confirmed that the level of tumor NF-κB inhibition 
generated by the CCNPs was sufficient to reduce the activation of the downstream 
prosurvival genes Bcl-xL and survivin, thus confirming that CCNPs reduce tumor size 
and number by blocking CPT-11 induced drug resistance.  Surprisingly, the free drug 
cocktail, which contained the same amount of CAPE as the nanoparticle formulations, 
caused a significant increase in NF-κB activation and had no effect on prosurvival mRNA 
levels.  These results demonstrate that the CCNP’s unique ability to localize high 
concentrations of CAPE to the tumor microenvironment is an essential factor in their 
ability to inhibit CPT-11-induced drug resistance.  This necessity to maximize the 
amount of CAPE in the tumor microenvironment validates our nanoparticle design and 
our use of PCAPE to formulate hyper-loaded nanoparticles.    
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To further explore the mechanism by which CCNPs reduce tumor size, we 
performed qPCR to quantify the tumor mRNA levels of TNFα and IL-1, which are 
cytokines known to promote tumor initiation, growth, and proliferation.   We discovered 
that although both CNPs, and CCNPs were able to reduce NF-κB activation levels in the 
tumors, only CCNPs were able to significantly reduce the tumor mRNA levels of TNFa 
and IL-1.  Given that both IL-1 and TNFα can be activated by soluble factors that act 
through NF-κB-independent pathways, we hypothesized that the increased levels of 
cytokine mRNAs in the tumors of mice treated with CNPs was the result of soluble 
proinflammatory factors that diffused into the tumor microenvironment.  We further 
postulate that by inhibiting tumor growth and tumorigenesis CCNPs are able to 
fundamentally transform the extra-tumor environment of the colon, and thus reduce the 
expression of soluble proinflammatory mediators that might diffuse into the tumor.   
Several preclinical studies have employed various NF-κB inhibitors as adjuvants 
to potentiate the efficacy of CPT-11 in the treatment of CRC.  Inhibition of NF-κB via the 
intratumoral adenoviral delivery of a super repressor form of IκBα in conjunction with 
systemic delivery of CPT-11 (57 mg kg-1 wk-1) resulted in a significant decrease in LoVo 
xenograft tumors94.  Although adenoviral mediated NF-κB suppression resulted in an 
impressive level of tumor inhibition, the challenges associated with viral mediated gene 
delivery are major obstacles blocking the clinical viability of this approach241,242.  In the 
same tumor model, the systemic administration of the proteasome inhibitor PS-341 
(Bortezomib) prior to treatment with CPT-11 (66 mg kg-1 wk-1) inhibited CPT-11-mediated 
NF-κB activation and generated an impressive decrease in tumor growth22.  Tumors 
treated with PS-341 and CPT-11 were 75% smaller than tumors treated with CPT-11 
alone.  A subsequent phase II trial that evaluated the effects of PS-341 on tumor growth 
showed that PS-341 did not decrease NF-κB levels in patients suffering from advanced 
CRC48.  These results call into question the clinical viability of PS-341 as an adjuvant for 
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CPT-11.  The radical scavenger edaravone has been shown to enhance CPT-11 (47 mg 
kg-1 wk-1) mediated apoptosis, tumor regression, and metastasis in mice bearing colon26 
xenograft tumors.  While effective in reducing CPT-11- induced NF-kB activation and 
tumor growth, the toxicity of edaravone is such that it is likely to limit its clinical 
application203.   A recent study26 showed that oral administration of the NF-κB inhibitor 
AS602868 (100 mg kg-1 wk-1) in combination with systemically delivered CPT-11 (60 mg 
kg-1 wk-1) lead to considerable growth suppression of HT-29 xenograft tumors.  After 10 
weeks of treatment, the combination of CPT-11 and AS602868 reduced tumor growth by 
75% compared to vehicle treated tumors26.  Nevertheless, after 4 weeks of therapy, the 
combination of CPT-11 and AS602868 was not significantly more effective than CPT-11 
alone.  Here, we show that treating mice with 3.0 mg-1 kg-1 wk-1 CPT-11 encapsulated in 
CCNPs generates a significant decrease in CAC tumor size and number.  Although it is 
impossible to compare studies performed on xenograft animal models to this study, it 
should be noted that mice treated with 4% CCNPs received almost 20 times less CPT-
11 per week than the lowest CPT-11 dose used in previously reported preclinical studies 
on CRC.     
In this work, we show that particles formulated from PCAPE localize to AOM-
induced tumors, inhibit tumor NF-κB activation, and thus potentiate the antitumor effects 
of encapsulated CPT-11 in an animal model of CAC.  Although studies have utilized 
pharmacological agents as a prophylaxis against AOM-induced oncogenesis243,244, to our 
knowledge, this is the first demonstration of a therapy that abrogates the growth of pre-
existing tumors and reduces subsequent tumorigenesis.  While designing CPT-11, we 
were careful not to incorporate features that were specific to CAC, and thus CCNP’s 
should have the chemical and physical properties necessary to treat a variety of solid 




Chapter 6:  Conclusion and Future Directions 
This work presents the preclinical development of two novel drug delivery 
platforms for treating diseases associated with intestinal inflammation.  Although these 
nanoparticles worked well in animal models of colitis and colitis-associated cancer, the 
ultimate goal is to develop these delivery vehicles into clinically viable products that can 
improve the quality of human life.  This section provides some concluding remarks, 
recommends additional experiments, and discusses the road to clinical translation.  
 
6.1. Thioketal Nanoparticles 
In Chapter 4, we presented a new polymer that could be formulated into 
nanoparticles that release therapeutics in response to (ROS) reactive oxygen species 
produced by inflamed intestinal tissue.  Given the immense potential of small interfering 
RNAs (siRNAs) and their demonstrated potential to treat inflammatory diseases, we 
chose to investigate the feasibility of targeting TNFα-siRNA to inflamed intestinal tissues 
as a treatment for inflammatory bowel disease (IBD), specifically ulcerative colitis.  We 
demonstrated that TKNs effectively targeted encapsulated siRNA to sites of intestinal 
inflammation, and when loaded with TNFα-siRNA mitigate inflammation in an 
experimental form of ulcerative colitis.  Although the work completed above is quite 
substantial and ground-breaking, questions remain about the ability of this system to 
treat IBD in human patients.   
In the preclinical studies performed above, the method for inducing intestinal 
inflammation via dextran sodium sulfate (DSS) does not result in physiological changes 
in the colon until day 2 or 3 of the experiment.  However, the mice are treated with the 
particles on the initial day of the experiment, then everyday thereafter.  Thus, the mice 
receive 3 to 4 days of treatment before inflammation is fully manifested in the colon.  
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Most patients do not take drugs before they acquire symptoms.  Accordingly, 
experiments should be conducted to determine if the TKNs, can rescue a mouse that is 
already suffering from intestinal inflammation.  Since the TKNs do not release 
therapeutics until ROS are increased in the colon, presumably at day 3 or 4, the initial 
doses probably have no effect on the ultimate outcome of the experiments presented 
above.  Therefore, we feel confident that the TKNs will be able to rescue a mouse from 
DSS-induced colitis.   
Although a brief discussion about the biological fate of the degradation products 
and un-degraded particles is provided in Chapter 5, a thorough investigation of the 
biodistribution of all degradation products, siRNA, and un-degraded particles needs to 
be performed in conjunction with a toxicological study of the material and its degradation 
products.  As discussed above, TKNs degrade into hydrophobic low molecular weight 
compounds, which should be cleared from the body.  Furthermore, we speculate that 
siRNAs released into the luman are either rapidly degraded or taken up by the 
endothelial layer, but not transcytosed, and thus do not enter the blood compartment.  
The results from the targeting experiments with siRNA support this hypothesis.       
We chose to use siRNA to silence TNFα expression; however, the current cost of 
such a therapeutic would prohibit its use for a non-life threatening disease.  However, 
nothing in the design of TKNs prohibits them from being utilized to delivery other, more 
reasonably priced, therapeutics that need to be targeted to inflamed intestinal tissues 
due to their potential toxicity.  As mentioned above in Chapter 2, currently, the most 
effective therapeutic for IBD are monoclonal antibodies against TNFα.  Encapsulating 
these antibodies in TKNs, and delivering them orally would reduce their toxicity and 
increase patient compliance. 
In this work, we synthesized PPADT from a monomer containing a benzene ring.  
We chose this monomer because it was commercially available and very hydrophobic, 
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which we hypothesized would help protect siRNA.  However, due to their ability to 
intercalate in genetic materials, benzene rings are not the most biocompatible structure 
that could be used.  Additionally, a more hydrophilic monomer would increase the TKN’s 
ROS sensitivity, which would result more siRNA being released as the particles traverse 
the GI tract, and better targeting of low levels of inflammation.  Although not shown here, 
we have indeed successfully synthesized polythioketals from a variety of other 
monomers.    
    
6.2. Poly-CAPE 
In Chapter 5, we presented a novel drug delivery platform capable of targeting 
CAPE and CPT-11 to AOM-induced tumors.  Our results show that CPT-11-loaded 
CAPE nanoparticles (CCNPs) were capable of inhibiting CPT-11-induced drug 
resistance.  In order to deliver a therapeutic quantity of CAPE to the tumor 
microenviroment, we incorporated CAPE into the backbone of a polymer via 
biodegradable linkages.  In a head-to-head experiment with an equivalent amount of free 
CAPE and CPT-11, the CCNPs elicited a significant reduction in tumor NF-κB, whereas 
the free drugs actually increased NF-κB activation in the tumors.  This result in concert 
with the targeting data, demonstrates that maximizing the concentration of CAPE in the 
tumor microenvironment is essential for potentiating the efficacy of CPT-11, and thus 
validates our efforts to maximize CAPE encapsulation by synthesizing PCAPE.    
Given the questionable nature of passive nanoparticle accumulation in human 
tumors, another platform that can actively target cancer tumors will have to be selected 
for clinical translation.  This could be accomplished by synthesizing a hyper-branched 
polymer that contained CAPE in its structure.  CPT-11 as well as targeting molecules 
could then be attached to the polymer, and the polymer delivered as a single strand.   
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Another interesting application of the CNPs is in the treatment of inflammatory 
diseases.  Aberrant NF-κB activation is a contributing factor to most inflammatory 
disorders.  In their current form, CNPs could be used to treat pulmonary fibrosis, 





































































Figure A1.1.  Thioketal nanoparticles have a toxicity profile simular to PLGA.  We 
determined that TNFα-TKNs have no detectable toxicity up to a dose of 5.0 mg/ml and that their 
toxicity profile is similar to that of TNFα-siRNA-loaded nanoparticles formulated from the FDA 






























Figure A1.2.  Extracellular TNFα mRNA levels as determined by ELISA.  To demonstrate 
the efficacy of TNFα-βGPs and TNFα-PLGA particles, macrophages were treated with 0.1 
mg/ml TNFα-siRNA contained within PLGA nanoparticles or βGPs, then activated by 
stimulating them with LPS.  After 24 h, these results show that both TNFα-PLGA and TNFα- 
βGPs reduced TNFα expression by activated macrophages.  Results depicted as mean pg of 
TNFα per ml of media ± s.e.m. for n = 3 per treatment group.  Statistical significance was 







































Figure A1.3. Cytokine profile for TKNs.  (a-c)  Fold increase of IFN-γ, IL-1, and IL-6 
mRNA in the colons of mice receiving DSS and treated with a daily oral gavage of 2.3 
mg/kg of either TNFα-siRNA or scrambled siRNA encapsulated within:  TNFα-TKNs (n = 
6), TNFα-PLGA (n = 5), Scram-TKNs (n = 5), siRNA-DOTAP (n = 6), or PBS (n = 6), for 
six days.  Statistical differences determined by a one-way ANOVA using Bonferroni’s 
post hoc test (*p ≤ 0.05, **p ≤ 0.001). 
 
 

























































































Figure A1.5. H&E-stained colon sections. (a) H&E-stained colon section of mice after 
seven days of receiving normal water and a daily oral gavage of PBS (10X).  (b-f) H&E-
stained colon sections for mice receiving DSS and treated with a daily oral gavage of PBS 
(b) or 2.3 mg/kg of either TNFα-siRNA or scrambled siRNA via:  (c) TNFα-PLGA, (d) TNFα-
TKNs, (e) Scram-TKNs, or (f) TNFα-DOTAP (10X). 
Figure A1.4.  Cytokine profile for β-glucan nanoparticles.  Colonic cytokine mRNA 
levels in mice receiving DSS and treated with either PBS or 0.23 mg TNFα-siRNA 
0.23/kg/day via βGPs (n = 10).  Statistical differences in Figures a-d determined by a one-







































Figure A1.6.  Colonic MPO activity.   Colonic MPO activity for mice receiving DSS and 
treated with 2.3 mg siRNA/kg/day.   Results are expressed as mUnits of MPO activity per 
mg protein.  Results represent the mean ± s.e.m., statistical significance was calculated 
using a one-way ANOVA and Bonferroni’s post hoc test (**p ≤ 0.001). 
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